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Ang  Angiopoietin 
BMDC  Bone marrow-derived cell 
CTL  Cytotoxic T lymphocyte 
DC  Dendritic cell 
EC   Endothelial cell 
EPC  Endothelial progenitor cell 
EGF(R) Epidermal growth factor (receptor) 
GFP  Green fluorescent protein 
HIF  Hypoxia inducible factor 
HER  Human epidermal growth factor receptor 
MCC  Merkel cell carcinoma 
MCPyV Merkel cell polyomavirus 
MMP  Matrix metalloproteinase 
NG-2  Neuronal-glial antigen 2  
NK cell  Natural killer cell 
PDGF(R) Platelet derived growth factor (receptor) 
PFU  Plaque forming unit 
PIGF  Placental growth factor 
PROK(R) Prokineticin (receptor) 
RT  Room temperature 
RTK   Receptor tyrosine kinase 
TAM  Tumor–associated macrophage 
VEGF(R) Vascular endothelial growth factor (receptor) 
vWF  von Willebrand factor 
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Tumor is more than a mass of transformed cells. Tumor cells are 
embedded in the supporting tumor stroma, that is composed of cellular 
and non-cellular components. The cellular components include vascular 
cells, bone marrow-derived cells (BMDCs), and fibroblasts. In concert, 
tumor cells and stromal cells secrete proteases, cytokines, chemokines, 
and growth factors that modulate the tumor behavior. The mechanisms 
how stromal cells contribute to the tumor growth and tumor 
angiogenesis are still incompletely understood.  
 
This thesis aimed to study the role of BMDCs in angiogenesis and 
cancer. First, the role of BMDCs as a source of vascular endothelium 
was examined. The second study addressed the effects of an EGFR 
inhibitor, gefitinib, on the vascular cells and BMDCs in an EGFR-
deficient B16 mouse melanoma tumor model. In the third study,  
chemokine-like prokineticins, that may have both angiogenic and 
immunomodulatory properties, were examined in a virus-associated 
human skin cancer type, Merkel cell carcinoma (MCC).  
 
BMDCs did not incorporate into the vascular endothelium in any of the 
experimental models, suggesting that the pre-existing vasculature is the 
main source of endothelium during angiogenesis. The potential of the 
BMDCs to differentiate into vascular endothelium may require specific 
molecular microenvironments, which needs further analysis. Treatment 
of B16 tumors with gefitinib reduced the pericyte number and coverage 
in the small CD31+ capillaries and the numbers of perivascular BMDCs 
suggesting that gefitinib treatment might have vascular and stromal 
effects in some tumors. The identity of the perivascular BMDCs that 
responded to treatment is not currently known, but the intimate 
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perivascular location of the affected cells proposes that these cells might 
contribute to tumor angiogenesis via paracrine mechanisms. In MCC, 
higher than median tumor prokineticin-2 (PROK2) mRNA content was 
strongly associated with the presence of Merkel cell polyomavirus 
(MCPyV) DNA, viral large T antigen expression, higher than median 
number of tumor infiltrating CD68+ and CD163+ macrophages, and 
with favorable survival. The presence of prokineticin-1 (PROK1) 
mRNA in the tumor was associated with absence of MCPyV DNA and 
tended to be associated with poor survival. Neither PROK1 nor PROK2 
mRNA content was associated with the tumor microvascular density. 
Taken together, these findings support the immunomodulatory role of 
prokineticins and suggest that prokineticins may be involved in 
mediating the immune response in MCC, but their role in tumor 
angiogenesis in MCC requires further evaluation.  +
+
 +
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In order to evolve to malignant cancer, tumor cells need to obtain 
several key capabilities. They need to be able to proliferate, show 
relative resistance to growth suppressors and cell death, obtain 
replicative immortality, induce the growth of the tumor vasculature, and 
finally to invade and metastasize from the site of origin. This does not 
occur cell-autonomously: malignant cells are accompanied with several 
types of resident and recruited stromal cells that contribute to the 
acquisition of these capabilities. The stromal cells form together with 
the extracellular matrix a cellular and molecular entity that is called the 
tumor microenvironment. The characteristics of the microenvironment 
are likely tumor type and stage specific (Hanahan, Weinberg 2011).  
 
The supporting stromal cells can be grouped roughly into three general 
classes: the vascular cells consisting of endothelial cells (ECs) and 
pericytes; infiltrating bone marrow-derived cells (BMDCs) and tissue-
resident immune cells; and fibroblasts (Figure 1). Like in normal 
inflammatory reactions, stromal cells may have both promoting and 
inhibiting functions in cancer. All three classes of cells may enhance 
tumor growth via paracrine secretion of several types of growth factors, 
survival factors, proangiogenic factors, and extracellular matrix–
modifying enzymes (Hanahan, Coussens 2012). BMDCs might also 
augment blood vessel growth by incorporating into the blood vessel 
endothelium as endothelial progenitor cells (Asahara et al. 1997, 
Asahara et al. 1999a). On the other hand, stromal cells, such as immune 
cells, may resist and even eradicate tumor development. Tumor cells 
may block such resistance mechanisms by secreting immunosuppressive 
factors and by recruiting naturally immunosuppressive cell types 
(Hanahan, Weinberg 2011). Therefore, the evolution of a tumor 
 11 
involves complex reciprocal crosstalk between tumor and stromal cells, 
but many of the cellular and molecular mechanisms involved still 
remain elusive.  
 
This thesis examined the contribution of BMDCs to tumor blood vessel 
endothelium and the effects of EGFR inhibition on tumor vascular cells 
and BMDCs. The expression of prokineticins, chemokine-like proteins 
that may have both angiogenic and imunomodulatory properties, was 
analyzed in a rare human skin tumor type, Merkel cell carcinoma, which 
likely has a viral origin.  
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1. Normal and pathological angiogenesis 
Angiogenesis is a rare event under normal physiological conditions and 
occurs only during the menstrual cycle and pregnancy, and during 
wound healing (Carmeliet, Jain 2011). Angiogenic stimuli trigger ECs 
of the pre-existing capillaries to sprout and to proliferate. This is 
thought to occur by a coordinated action of sprouting tip cells and 
proliferating stalk cells leading through pruning and remodeling to a 
mature vascular network composed of a highly organized hierarchy of 
larger vessels and smaller capillaries (Geudens, Gerhardt 2011).  
 
The vascular basement membrane is an important component in the 
initiation and resolution of angiogenesis. Its degradation and 
remodelling by proteinases, such as matrix metalloproteinases, is one of 
the early steps in the angiogenic sequence that allows the ECs to sprout, 
proliferate, and invade the surrounding extracellular matrix. Basement 
membrane degradation also releases angiogenic growth factors and anti-
angiogenic molecules bound to the matrix (Kalluri 2003). During 
sprouting and EC migration, the basement membrane provides guidance 
and a scaffold for tube assembly. The new EC tubes formed are 
stabilized by attachment of pericytes and secretion of basement 
membrane components that change the ECs from a highly active state 
back to a relatively quiescent state (Carmeliet, Jain 2011, Davis, Senger 
2005).  
 
In some organs, angiogenesis may occur via a non-sprouting 
mechanism, where an existing blood vessel is divided into two by 
transcapillary pillars of the extracellular matrix (Carmeliet, Jain 2011). 
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During embryonic development, the first blood vessels are generated by 
vasculogenesis, de novo formation of ECs from mesenchymal 
angioblasts that differentiate into ECs. The primary capillary plexus 
formed by vasculogenesis then serves as a scaffold for sprouting 
angiogenesis (Risau, Flamme 1995).  
 
As all cells, tumor cells need an adequate supply of oxygen and 
nutrients to grow. To accomplish this, tumors induce the growth of their 
own vasculature after reaching approximately 1 mm size, that is the 
diffusion limit for oxygen (Folkman 1971). Induction of angiogenesis in 
a dormant tumor is thought to occur through a discrete step called an 
“angiogenic switch” that changes the tumor from dormant to vascular 
state. The timing of the switch likely depends on the tumor type. In 
some tumors, tumor cells are able to grow around existing vessels 
(vessel co-option), and do not, at least initially, need new vasculature 
(Bergers, Benjamin 2003). Angiogenesis in tumors leads to chaotic, 
poorly organized vasculature with irregularly shaped, dilated and leaky 
vessels. The typical vessel hierarchy, a characteristic of normal tissues, 
is missing (Carmeliet, Jain 2011). This is due to multiple cellular 
abnormalities reviewed in the following sections. 
 
1.1 Endothelial cells 
The inner cellular lining of the blood and lymphatic vasculature consists 
of an EC monolayer. Despite their slow cell cycling under normal 
conditions, ECs are metabolically very active cells that participate in 
several physiological functions including controlling of the vascular 
tone, blood cell trafficking, hemostatic balance, vascular permeability, 
and the regulation of immune responses (Aird 2007 a).  
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ECs exhibit great structural, functional and molecular heterogeneity 
between different types of tissues and vessel types. In the arteries, ECs 
are long and narrow cells typically aligned in the direction of the blood 
flow. In the veins, ECs are much shorter and wider. Due to a low blood 
pressure the ECs are remarkably thin in the capillaries, less than 0.1 µm. 
Three types of endothelium have been identified: continuous non-
fenestrated endothelium, continuous fenestrated endothelium, and 
discontinuous endothelium. In continuous endothelium, ECs have tight 
connections and are surrounded by a continuous vascular basement 
membrane (Aird 2007a). In some vascular beds, such as in the 
glomerular endothelium of the kidneys, the continuous endothelium is 
permeated with holes (fenestrae) needed for increased filtration and 
trans-endothelial transport. In discontinuous endothelium, found for 
example in the liver, the fenestrae are accompanied by an incompletely 
formed basement membrane (Aird 2007b).  
 
Different vascular beds and different vessel types in the same vascular 
bed express different proteins (Page et al. 1992, Aird 2007a). For 
example, the von Willebrand factor (vWF) is more strongly expressed 
in larger vessels as compared to microvessels, and in venous ECs 
compared to arterial ECs (Yamamoto et al. 1998).  None of these 
proteins is considered EC-specific. The vWF is also present in platelets 
and the subendothelial matrix, and other EC proteins, such as 
platelet/EC adhesion molecule-1 (PECAM-1 or CD31) and the vascular 
endothelial growth factor receptor-2 (VEGFR -2), are also found in 
hematopoietic cells (Ruggeri, Ware 1993, Ziegler et al. 1999, Baumann 
et al. 2004).  
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Tumor ECs proliferate actively and do not form a tight monolayer, 
which causes vessel leakiness (Hashizume et al. 2000). The altered 
structural and functional properties are associated with aberrant gene 
and protein expression profiles. Molecular heterogeneity may exist 
between the blood vessels of a single tumor, between different stages of 
tumor progression, and between different tumor types (Baluk et al. 
2005). In some tumors, blood vessels may be partially lined by tumor 
cells instead of ECs, known as vasculogenic mimicry  (Folberg et al. 
2000).  ECs may also originate from the BMDCs or from tumor cells 
via transdifferentiation (Asahara et al. 1997, Lyden et al. 2001, Wang et 
al. 2010, Ricci-Vitiani et al. 2010, Soda et al. 2011). 
 
1.1.1 Endothelial progenitor cells  
Mature ECs can be shed off from the vascular wall into the blood 
circulation. In 1997, Asahara and colleagues found that the human 
peripheral blood contains another EC population that expressed CD34 
and/or VEGFR-2 markers and had a higher proliferative potential than 
the mature ECs. When cultured in vitro, this population expressed 
endothelial markers, such as CD31 and E-selectin, and these cells were 
localized to the vascular regions during ischemic conditions and in 
tumors in vivo (Asahara et al. 1997, Asahara et al. 1999a). In the 
subsequent studies, it was shown that these putative endothelial 
progenitors (EPCs) are mobilized from the bone marrow to the 
circulation in response to angiogenic cytokines, tissue ischemia and 
tumors (Hattori et al. 2001a, Takahashi et al. 1999, Asahara et al. 
1999b). EPCs were even found to be necessary for tumor 
vascularization in an angiogenesis-defective mouse model (Lyden et al. 
2001). However, in other studies the contribution of these cells to blood 
vessel endothelium has varied extensively, which likely reflects the 
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differences in the experimental models (Gao et al. 2008, Nolan et al. 
2007, Peters et al. 2005, Rajantie et al. 2004, Gothert et al. 2004, 
Ziegelhoeffer et al. 2004, De Palma et al. 2003, Garcia-Barros et al. 
2003). The selection of the imaging method may also affect the results, 
because the vascular wall has two distinct cell populations in close 
proximity (Rajantie et al 2004). The variability in the experimental 
approaches between different studies makes a systematic comparison 
challenging, and the lack of consensus in the field regarding the 
minimal set of parameters needed to confirm that a cell of 
hematopoietic origin has differentiated into an EC has kept the debate 
on the existence of bone marrow-derived EPCs ongoing (Yoder, Ingram 
2009).  
 
The phenotypic identification of circulating EPCs has been based on 
two approaches: 1) cell adhesion and growth in vitro, and 2) cell surface 
phenotype assessed with fluorescently labeled antibodies and flow 
cytometry. A limitation of both approaches is the lack of a unique set of 
cell surface markers to distinguish EPCs from other circulating cell 
populations (Hirschi et al. 2008). Initially human EPCs were identified 
with surface markers CD34 and VEGFR-2 (Asahara et al. 1997). Later, 
CD133 was added to the phenotype (Gehling et al. 2000). However, it 
was shown that the majority of cells extracted with this marker profile 
are not progenitors for the endothelium, but a heterogeneous population 
of hematopoietic progenitors and mature hematopoietic cells that are 
able to mimic the ECs morphology, and expressed endothelial markers 
in the in vitro conditions that were used for culture (Desai et al. 2009, 
Rohde et al. 2007, Yoder et al. 2007, Case et al. 2007, Gulati et al. 
2003). It has been proposed that the term EPC, when referring to a 
heterogeneous mixture of cells, should be retired, and each cellular 
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subset should be redefined based on its phenotype and function 
(Richardson, Yoder 2011).    
 
Recent data suggest that the cells with the most potential to function as 
EC progenitors might reside in the cell population that emerges 14 days 
after plating of human blood mononuclear cells (Fadini et al. 2012, 
Hirschi et al. 2008). These so-called late EPCs/endothelial colony 
forming cells/blood outgrowth cells express endothelial markers 
(VEGFR-2, CD34, vWF, endothelial nitric oxide synthase, vascular 
endothelial-cadherin), lack several hematopoietic markers (CD45, 
CD14, CD115), do not ingest bacteria, have a high proliferative 
potential, form blood vessel-like structures in vitro, and integrate into 
the vascular wall in vivo (Medina et al. 2010, Hirschi et al. 2008, 
Timmermans et al. 2007, Ingram et al. 2004). The number of human 
late EPCs is low, and in mice these cells are apparently very rare, 
because blood from 4 to 6 mice gave rise to successful growth of late 
EPCs in vitro only in 28% of the attempts (Somani et al. 2007). The 
exact origin of late EPCs is not known. Interestingly, some studies 
indicate that a pool of endothelial stem cells/progenitor cells may reside 
within the vascular wall (Schniedermann et al. 2010, Naito et al. 2011, 
Ingram et al. 2005, Huang et al. 2010, Fang et al. 2012)  
 
1.2 Pericytes  
Two types of perivascular cells are known, the pericytes (the Rouget 
cells/mural cells) and the smooth muscle cells. Pericytes are mainly 
found in microvessels, while smooth muscle cells are present in larger 
vessels (Armulik et al 2005). Smooth muscle cells compose a zone 
called the media, and are separated from the endothelium by a layer of 
mesenchymal cells and extracellular matrix, the intima (Andreeva et al. 
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1998). Pericytes in smaller capillaries have a very close association with 
the endothelial layer and are embedded together with the ECs into the 
vascular basement membrane. However, intermediate size vessels may 
have perivascular cells having properties both from the smooth muscle 
cells and the pericytes. The pericyte to the EC ratio and the pericyte 
morphology may also vary in different tissues and different types of 
vessels, which is likely due to the different metabolic demands. 
Pericytes are generally less abundant in organs with very active 
exchange of gas or metabolites (Armulik et al. 2011) . 
 
Markers that have been used to identify the pericytes include smooth 
muscle !-actin, the chondroitin sulphate proteoglycan neuronal-glial 
antigen-2 (NG-2), desmin, and the platelet derived growth factor 
receptor beta (PDGFR-") (Herman, D'Amore 1985, Skalli et al. 1989, 
Nehls, Drenckhahn 1991, Sundberg et al. 1993, Ozerdem et al. 2001). 
However, these markers are not specific for the pericytes, and none of 
these markers recognizes all pericytes. PDGFR-" and NG-2 have been 
implicated as early pericyte markers, while smooth muscle actin is a late 
marker for the more differentiated pericytes and smooth muscle cells, 
and it may be poorly expressed in the developing angiogenic 
microvasculature (Nehls, Drenckhahn 1991, Ozerdem, Stallcup 2003).  
 
The pericytes may have multiple origins, and the origin may depend on 
the vascular bed. In embryos, the perivascular cells may originate either 
from the mesoderm, the neural crest or from the endothelium 
(Bergwerff et al. 1998, DeRuiter et al. 1997, Hungerford et al. 1996). In 
adults, pericytes may be recruited from local immature mesenchymal 
cells or from the bone marrow (Abramsson et al. 2002, Sata et al. 2002, 
Rajantie et al. 2004, Bababeygy et al. 2008). Local recruitment might be 
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derived either from the neighboring adipose tissue or from the proposed 
multipotent stem cells that are located in the vascular wall (Klein et al. 
2011, Kidd et al. 2012).  
 
The pericytes are ideally located for taking actively part in 
angiogenesis. Their detachment allows angiogenic factors to stimulate 
the ECs, which start secreting several proteases to degrade the basement 
membrane. Consequently, ECs are able to invade into the surrounding 
extracellular matrix and to form a column of migrating and proliferating 
cells. In some cases, the pericytes might be capable of guiding the 
sprouting process  (Ozerdem, Stallcup 2003, Amselgruber et al. 1999, 
Tigges et al. 2008). However, angiogenic sprouting occurs normally in 
PDGFR-" mutant embryos lacking the pericytes (Hellstrom et al. 2001). 
The attachment of the pericytes to the ECs is important for vessel 
stabilization and maturation, and lack of pericytes causes variation of 
the capillary diameters and leaking vasculature (Benjamin et al. 1998, 
Bjarnegard et al. 2004).  
 
Tumor pericytes are loosely attached to the vasculature and extend their 
cytoplasmic processes into the tumor stroma. The loose attachment may 
increase the tumor potential for metastasis (Xian et al. 2006). 
Differences exist also in the abundance of pericytes and in their gene 
expression profiles between tumors (Morikawa et al. 2002). In cancer, 
abnormalities are found also in the basement membrane. In general, it is 
present and it surrounds most endothelial sprouts and pericyte 
processes, but it has a loose association with the ECs, may consist of 
multiple redundant layers, and may have irregular thickness, focal 
holes, and broad extensions into the tumor stroma (Baluk et al. 2003).  
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2. Angiogenic signaling pathways 
Several signaling families are involved in regulating the angiogenic 
cascade (Figure 2). Those pathways that are most relevant to this thesis 
are reviewed in the following sections. Three pathways of these 
pathways are canonical angiogenic pathways: the vascular endothelial 
growth factor (VEGF) family, the PDGF family and the 
Tie/Angiopoietin family, whereas the other two pathways have a less 
established role in the angiogenesis: the epidermal growth factor (EGF) 
family and the prokinetin family. In addition to the pathways reviewed 
herein, angiogenesis engages several other molecular families, such as 
the fibroblast growth factor family, chemokines, notch, semaphorins, 
and ephrins (Weis, Cheresh 2011). 
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2.1 The VEGF family  
The VEGF family consists of three receptors (VEGFR-1, -2 and -3) and 
six ligands (VEGF-A, -B, -C, -D, -E, and the placental growth factor, 
PlGF). VEGF-A is the key angiogenic factor as its expression alone is 
capable of initiating angiogenesis in a quiescent vasculature. At least six 
isoforms of VEGF-A are produced, but VEGF164 is the main effector of 
VEGF-A actions, since mice expressing only this isoform are viable and 
healthy (Stalmans et al. 2002). VEGF-A knockout mice die at 
embryonic days 8-9 due to defects in the blood island formation and 
vascularization, and even the lack of a single VEGF-A allele in mice 
leads to early embryonic lethality at embryonic days 11-12 (Ferrara et 
al. 1996). 
 
High expression levels of VEGF-A are detected at angiogenic sites. 
VEGF-A expression is induced by tissue oxygen levels via hypoxia-
inducible factor-1 (HIF-1) (Shweiki et al. 1992, Forsythe et al. 1996). 
VEGF-A mediates its biological effects via binding to receptor tyrosine 
kinases (RTKs) VEGFR-1 and VEGFR-2. VEGFR-1 has higher affinity 
to VEGF-A, but VEGF binding to VEGFR-2 has a stronger mitogenic 
effect on ECs (Waltenberger et al. 1994). However, both receptors are 
necessary during the embryonic development (Shalaby et al. 1995, Fong 
et al. 1995).  
 
The actions of VEGF-A during angiogenesis are complex. VEGF-A 
acts primarily on ECs and induces EC proliferation, sprouting, 
migration, tube formation, permeability, and survival (Ferrara at al. 
2003). In the retinal vasculature, VEGF-A promotes pericyte 
recruitment that accelerates vessel stabilization (Benjamin et al. 1998).  
However, VEGF-A may also act as a negative regulator for the 
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pericytes (Greenberg et al. 2008). VEGF receptors are found also on 
hematopoietic cells, and VEGF-A is known to regulate their chemotaxis 
and survival (Clauss et al. 1990, Barleon et al. 1996, Sawano et al. 
2001, Gerber et al. 2002). VEGF-A is produced by several cell types, 
such as tumor cells, pericytes, macrophages, and platelets (Salven et al. 
1999, Leek et al. 2000, Darland et al. 2003). In tumors, the source of 
VEGF-A may depend on the tumor type (Sennino et al. 2009).  
 
VEGF-A is important for pathological angiogenesis. In the mouse 
model of pancreatic islet carcinoma, conditional VEGF-A knockout in 
tumor cells results in decreased tumor vascular density, whereas the 
overexpression of VEGF-A enhances angiogenic switch and tumor 
growth (Inoue et al. 2002, Gannon et al. 2002). In the intestinal 
epithelial cells of Apcmin+/min mice, conditional VEGF-A knockout 
results in delayed adenoma growth (Korsisaari et. al. 2007). 
Furthermore, overexpression of VEGF-A in tumor cells has been shown 
to shorten tumor latency, to enhance tumor growth, and to increase 
vascular density in the mouse mammary carcinomas (Schoeffner et al. 
2005). In mouse skin tumors, deletion of VEGF-A causes tumor 
regression whereas overexpression accelerates tumor growth. 
Interestingly, besides its known effect on tumor angiogenesis, VEGF-A 
has also been found to promote cancer stem cell division (Beck et al. 
2011). 
 
Much less is known about other ligands of this family. VEGF-B and 
PlGF are ligands for VEGFR-1, and they are redundant for 
developmental angiogenesis. VEGF-B knockout mice are viable and 
fertile although they have minor defects in the heart vasculature 
(Bellomo et al. 2000). Similarly, PlGF knockout mice do not have 
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major developmental defects, but deletion of the PlGF reduces 
pathological angiogenesis, permeability and collateral growth during 
ischemia, inflammation, wound healing, and cancer (Carmeliet et al. 
2001).  
 
VEGF-C and VEGF-D are primarily lymphangiogenic factors that 
induce the growth of lymphatic vessels in the embryo and during 
adulthood via binding to the VEGFR-3. VEGF-C knockout is lethal in 
mice embryos due to defects in the lymphatic development (Karkkainen 
et al 2004), whereas VEGF-D knockout mice are viable and fertile 
(Baldwin et al. 2005). The last member of the family, VEGF-E, refers to 
a group of VEGF-related proteins of viral origin. VEGF-E has been 
shown to induce angiogenesis in vitro and in vivo via the VEGFR-2 
(Meyer et al. 1999, Kiba et al. 2003).  
 
2.2 The PDGF family 
The PDGF family consists of four ligands  (PDGF-A, -B, -C and –D) 
and two RTKs (PDGFR-! and PDGFR-"). As with other receptor 
tyrosine kinases, binding of the ligands leads to dimerization of the 
RTKs. PDGF-A and PDGF-C bind to PDGFR-!!, and PDGF-B and 
PDGF-D to PDGFR-"". In some special cases, also heterodimeric 
receptor complexes may be present, but the homodimers dominate. 
PDGF-A and PDGF-C are expressed in epithelial cells, and in muscle 
and neuronal progenitors, whereas PDGF-B is mainly expressed in the 
vascular ECs, megakaryocytes and neurons. PDGF-D expression has 
been observed in fibroblasts and smooth muscle cells (SMCs). PDGFR-
! and PDGFR-" are expressed in mesenchymal cells, and PDGFR-" 
particularly in the vascular SMCs and the pericytes (Andrae et al. 2008).  
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PDGFs promote vascular growth (Cao et al. 1998, Li et al. 2003, Risau 
et al. 1992). Best understood is the PDGF-B/PDGFR-" signaling axis 
that participates in mediating pericyte proliferation and recruitment into 
the vasculature. PDGF-B and PDGFR-" knockout mice have abnormal 
vessels showing a lack of pericytes and endothelial hyperplasia (Leveen 
et al. 1994, Soriano 1994, Lindahl et al. 1997, Hellstrom et al. 1999, 
Hellstrom et al. 2001). Endothelium-specific PDGF-B knockout mouse 
has a similar phenotype indicating that the ECs are the main source of 
PDGF-B (Enge et al. 2002, Bjarnegard et al. 2004). The cellular 
localization of PDGF-B is regulated by a retention motif that keeps it in 
the perivascular space. Deletion of the motif or defective heparan 
sulfate on the cell surface causes improper pericyte recruitment 
indicating that PDGF-B is an essential factor for the pericyte during 
development (Lindblom et al. 2003, Abramsson et al. 2007).  
 
PDGF signaling mediates the recruitment of pericytes and fibroblasts 
also during tumor growth  (Abramsson et al. 2003, Anderberg et al. 
2009, Forsberg et al. 1993, Tejada et al. 2006, Furuhashi et al. 2004). 
Pharmacological blockade of PDGR-" inhibits tumor growth by 
reducing the vascular pericyte coverage (Bergers et al. 2003, Shaheen et 
al. 2001). The PDGF-B/PDGFR-" signaling axis might be involved in 
coordinating lymphatic metastasis (Schito et al. 2012, Kodama et al. 
2010).  PDGF-A has been shown to recruit VEGF-A secreting 
fibroblasts in VEGF-A depleted tumors thus rescuing tumor 
angiogenesis (Dong et al. 2004). In addition to the paracrine 
mechanisms, autocrine PDGF signaling has been shown to promote the 
development of certain brain tumors (Dai et al. 2001, Uhrbom et al. 
1998, Lokker et al. 2002).  
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2.3 The angiopoietin/Tie family 
The angiopoietin (Ang) growth factor family contains three growth 
factors: Ang1, Ang2, and Ang3/4 (a mouse/human ortholog, 
respectively) (Davis et al. 1996, Maisonpierre et al. 1997, Valenzuela et 
al. 1999)  Angiopoietins bind to the Tie RTKs (Dumont et al. 1992, 
Partanen et al. 1992, Sato et al. 1993). The Tie receptors are 
preferentially expressed on the endothelium, but Tie2 is also found on 
hematopoietic cells (De Palma et al. 2005, Tang et al. 2010, Murdoch et 
al. 2007). Ang1 is mostly expressed by the perivascular cells, such as 
the pericytes, SMCs, and fibroblasts (Patan 1998, Davis et al. 1996). 
Ang2 is found in the ECs and in the pericytes/SMCs (Fiedler et al. 
2004, Gale et al. 2002, Maisonpierre et al. 1997). The angiopoietins 
localize differentially in the stromal compartments: Ang1 binds to the 
extracellular matrix, Ang2 is freely soluble, and Ang3 is tethered to the 
cell surface via the heparan sulphate proteoglycans  (Xu et al. 2004b, 
Xu, Yu 2001).  All ligands bind to Tie2, but Ang1 and Ang4 may also 
signal via Tie1. However, the presence of Tie2 is required for full Tie1 
activation (Saharinen et al. 2005). The Ang1, Tie1, and Tie2 knockout 
mouse phenotype is lethal, and the mice die from abnormalities in the 
embryonic vasculature (Suri et al. 1996, Puri et al. 1995, Sato et al. 
1995). Ang2 is dispensable for embryonic angiogenesis, but adult 
Ang2-deficient mice have several vascular defects (Hackett et al. 2002, 
Gale et al. 2002). 
 
The angiopoietins regulate vessel quiescence, remodeling, and 
maturation. In vitro, Tie2 activation by Ang1 promotes EC survival and 
stimulates EC proliferation, sprouting, and tube formation (Kim et al. 
2000, Hayes et al. 1999, Kwak et al. 1999, Koblizek et al. 1998). Ang1 
overexpression in vivo induces vessel sprouting, enlargement, and 
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vessel maturation by recruiting perivascular cells and by reducing 
permeability (Suri et al. 1998, Thurston et al. 1999, Thurston et al. 
2000). However, the role of Ang1 in vessel maturation seems to be 
dependent on PDBF-B (Fuxe et al. 2011). Ang1 has also an anti-
inflammatory role as it reduces the expression of proinflammatory 
genes in the ECs (Gamble et al. 2000, Kim et al. 2001).  
 
In contrast, Ang2 promotes the inflammatory response (Fiedler et al. 
2006). Vascular Ang2 expression increases myeloid cell infiltration and 
improves responsiveness during acute inflammation (Scholz et al. 
2011). Ang2 is a destabilizing factor for the blood vessels. It is absent in 
a quiescent endothelium but is quickly upregulated upon an angiogenic 
stimulus (Maisonpierre et al. 1997, Suri et al. 1996). In the retina, 
increased Ang2 expression induces dissociation of the pericytes and 
increases vascular permeability (Hammes et al. 2004). However, Ang2 
can take a supportive role when Ang1 is absent to maintain EC 
homeostasis (Yuan et al. 2009). Ang2 expression is regulated by several 
growth factors and hypoxia, and it shows a cyclic expression pattern in 
the ovaries (Goede et al. 1998, Oh et al. 1999, Mandriota, Pepper 1998). 
Ang2 expression is frequently elevated in tumors, and its expression has 
been shown to correlate with malignancy (Bach et al. 2007).  
 
The actions of Ang3/Ang4 in angiogenesis have not been studied 
extensively. Both factors are able to induce angiogenesis in a mouse 
corneal micropocket assay proposing an agonist role (Lee et al. 2004). 
However, like with other angiopoietins, their function might depend on 
the context  (Xu et al. 2004a, Beaudet et al. 2010).  
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2.4 Other pathways 
2.4.1 The EGF family 
The EGF family consists of four receptors and 11 EGF-like growth 
factors. The receptors include EGFR/HER1/ErbB1, ErbB2/HER2/Neu, 
ErbB3/HER3 and ErbB4/HER4. The receptors form either homo- or 
hetero-dimers upon ligand binding. The ligands can be classified into 
four groups based on their binding specificity to the receptors. EGF, 
transforming growth factor-!, epigen, and amphiregulin bind only to 
the EGFR. Heparin-binding EGF-like growth factor, betacellulin, and 
epiregulin bind to both EGFR and ErbB4. Neuregulins 1 and 2 bind to 
both ErbB3 and ErbB4, whereas neuregulins 3 and 4 bind to ErbB4 
alone. ErbB2 does not have any known ligands (Yarden, Sliwkowski 
2001). The ligands are produced as transmembrane precursors that are 
processed to mature growth factors via proteolytic cleavage of the 
ectodomain, but also some membrane-anchored forms can mediate 
signaling (Sanderson et al. 2006). The epidermal growth factor receptor 
(EGFR) was the first RTK that was linked to cancer (Gschwind et al. 
2004). EGFR is important in the etiology of several epithelial tumors. 
Increased EGFR signaling induces excess proliferation, migration, 
invasion of tumor cells, and angiogenesis (Yarden, Sliwkowski 2001). 
 
EGF family ligands are potent pro-angiogenic factors. Most of the 
angiogenic effect is likely mediated indirectly via activating canonical 
angiogenic pathways in tumor cells, such as the VEGF pathway (De 
Luca et al. 2008). However, ligands might stimulate the ECs also 
directly. It has been shown that EGF induces angiogenesis in avascular 
areas of mouse corneas, and EGFR inhibitor gefitinib almost completely 
blocks EGF –induced neovascularization (Hirata et al. 2002). EGFR 
expression has been found in ECs of prostate cancer, tumor xenografts 
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of melanoma, and in pancreatic and renal tumors (Baker et al. 2002, 
Kedar et al. 2002, Amin et al. 2006, Sini et al. 2005, Kim et al. 2003). 
EGFR has not been studied much in other stromal populations of the 
tumor. However, recent data indicates that EGFR might be present also 
on perivascular cells in some tumors (Nolan-Stevaux et al. 2010, 
Cascone et al. 2011). 
 
2.4.2 The prokineticin family 
The prokineticin family contains two ligands: prokineticin-1 (PROK1) 
and prokineticin-2 (PROK2 or Bv8), and two G-protein coupled 
receptors, prokineticin receptor-1 (PROKR1) and prokineticin receptor-
2 (PROKR2) (Li et al. 2001, Lin et al. 2002). Both ligands bind to both 
receptors, but PROK2 has a higher affinity. The ligands share many 
common features with the chemokines, such as a small size, signaling 
via the G-protein coupled receptors, the signaling mechanism, and 
chemotactic functions, but differ in th patterns of their genomic 
organization. The genes of the major chemokine subfamilies, such as 
those of the CXC chemokines, are frequently clustered on the same 
chromosome, whereas the genes encoding the prokineticin family 
members are located in different chromosomes (Negri et al. 2007). 
Interestingly, the prokineticin ligands have the closest homology with 
the defensins, which are a family of microbicidal defense peptides 
(Monnier, Samson 2008). Prokineticins are involved in several 
physiological processes, such as gastrointestinal motility, circadian 
rhythms, pain sensation, neural developments, immune response as well 
as angiogenesis (Monnier, Samson 2010).   
 
The prokineticin ligands give a potent angiogenic response and are 
upregulated in hypoxic tissue regions.  Both ligands possess also a HIF-
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1 binding site at the promoter region, implying that prokineticins are 
regulated by hypoxia (LeCouter et al. 2003, LeCouter et al. 2001). The 
prokineticin receptors are found on the ECs in several tissues, and the 
receptors may result in divergent responses in the ECs upon stimulation 
(Podlovni et al. 2006, Guilini et al. 2010, Brouillet et al. 2010). PROK1 
is mostly expressed in steroidogenic glands, whereas PROK2 can be 
also found in the bone marrow, circulating leukocytes, and resident 
organ immune cells. PROK2 expression is frequently induced in 
inflamed tissues (Watson et al. 2012, Giannini et al. 2009, Choke et al. 
2009, LeCouter et al. 2004, Cheng et al. 2012). PROK1 and PROK2 
have been shown to mediate hematopoietic cell mobilization, monocyte 
chemotaxis, and hematopoietic colony formation (LeCouter et al. 2004). 
Myeloid cell-derived PROK2 induces tumor angiogenesis in some 
mouse tumor models (Shojaei et al. 2009, Shojaei et al. 2007b, Shojaei 
et al. 2008, Lu et al. 2012, Shojaei et al. 2007a). Expression of the 
prokineticin family members has been studied in few human tumors, but 
their relevance to human tumor growth was dependent on the tumor 
type (Monnier, Samson 2010) which will be reviewed in more detail in 
the discussion part.  
 
3. BMDCs and fibroblasts in host defense and angiogenesis 
The tumor stroma is composed of vascular cells, BMDCs, and 
fibroblasts. Vascular cells were reviewed in chapter 1 whereas the other 
cell types are reviewed in the following sections.  
 
Hematopoietic stem cells are located at the top of the hierarchy of 
BMDC progenitors that yield myeloid and lymphoid lineages (Figure 
3). The immediate progeny of stems cells are multipotent progenitor 
cells that are still able to produce all blood lineages but have restricted 
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capacity to self-renew. Multipotent progenitor cells produce progenitors 
that are restricted to yield either myeloid or lymphoid cells. Committed 
lineage–restricted progenitors yield unipotent precursors, which further 
differentiate into mature blood cells (Bryder et al. 2006). +
+
+
+
+
+
+
+
+
+
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+
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3.1 Myeloid cells  
Myeloid lineage cells form the first line of host defence. Recognition of 
a foreign peptide or an abnormal cell triggers tissue-resident mast cells 
and macrophages to release growth factors and chemokines that 
mobilize and recruit myeloid cells. Neutrophilic granulocytes are 
recruited first, followed by monocytes that further differentiate into 
macrophages and dendritic cells (DCs) (de Visser et al. 2006). 
Macrophages might also accumulate in inflamed tissues via local 
proliferation (Jenkins et al. 2011, Gordon, Taylor 2005). Macrophages 
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are the main source of growth factors and cytokines that affect the local 
microenvironment. 
 
HIF-1! that is stabilized by low tissue oxygen is essential for 
inflammation. Overexpression of HIF-1! increases inflammation, 
whereas the loss of HIF-1! reduces myeloid cell responsiveness to 
bacterial infections (Cramer et al. 2003). HIF-1! regulates the 
expression of several angiogenic target genes (Liao, Johnson 2007). 
HIF-1! also promotes inflammatory cell recruitment to tumors (Du et 
al. 2008).  
 
Inflammation is self-limiting, but sometimes the inhibitory mechanisms 
fail leading to a persisting inflammatory state. Chronic inflammation 
may predispose to cancer. In epidemiological studies it has been 
estimated that 15-20% of cancers have an infectious or inflammatory 
origin (Balkwill, Mantovani 2001). One of the best-known examples is 
Helicobacter pylori infection, which is associated with an increased risk 
for gastric carcinoma (Parsonnet et al. 1991). Viruses linked with 
human cancer include human papillomavirus, Epstein-Barr virus, 
Kaposi’s sarcoma herpesvirus, hepatitis B virus, hepatitis C virus, 
human T-cell leukemia virus, and some human polyomaviruses (Pagano 
et al. 2004). Also genetic alterations may stimulate cellular 
proinflammatory pathways (Shchors et al. 2006, Borrello et al. 2005, 
Sparmann, Bar-Sagi 2004).  
 
3.1.1 Macrophages 
A large proportion of the tumor mass may consist of tumor-associated 
macrophages (TAMs). TAMs are thought to originate from the recruited 
 32 
circulatory monocytes, but also sites of extramedullary hematopoiesis, 
such as the spleen, may contribute to the TAM pool by supplying TAM 
progenitors (Cortez-Retamozo et al. 2012). Normal macrophages are 
capable of lysing abnormal cells, presenting antigens to T cells, and 
expressing cytokines that stimulate the adaptive immune response. In 
most tumors, these activities are greatly reduced, and the TAMs are 
activated via alternative pathways resulting in TAM-secreted factors 
enhancing tumor cell proliferation, extracellular matrix remodeling, 
tumor cell migration, angiogenesis, invasion, and metastasis. However, 
the TAMs may exist in different activation states within the same tumor 
(Sica, Mantovani 2012). Patients with a solid tumor and a high density 
of TAMs generally have poor prognosis (Zhang et al. 2012, Bingle et al. 
2002, Edin et al. 2012). In some cases, the TAMs may predict responses 
to cancer treatment. For example, in Hodgkin’s lymphoma, a high 
number of macrophages correlates with treatment failure (Steidl et al. 
2010). 
 
Wounds and tumors are frequently hypoxic and hypoxia is a major 
driver of angiogenesis. TAMs often accumulate in hypoxic areas in 
tumors (Lewis, Murdoch 2005). The TAM numbers in tumor samples 
correlate with an increasing tumor vascularity (Leek et al. 1996, Nishie 
et al. 1999). The TAMs secrete proangiogenic factors and extracellular 
matrix-remodeling proteinases, including VEGF-A, interleukin-1, and 
matrix metalloproteinase 9 (MMP-9) (Leek et al. 2000, Lewis et al. 
2000, Coussens et al. 2000, Voronov et al. 2003, Bingle et al. 2006, 
Ahn, Brown 2008, Du et al. 2008, Hao et al. 2008). In the mouse model 
of breast cancer, inhibition of TAM infiltration delays the angiogenic 
switch and metastasis (Lin et al. 2006). During cervical tumourigenesis, 
blockade of MMP-9, that is mostly produced by TAMs, reduces the 
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release of VEGF-A from the extracellular matrix inhibiting tumor 
growth and angiogenesis  (Giraudo et al. 2004). On the other hand, 
depletion of VEGF-A in myeloid cells induces vessel normalization that 
accelerates tumor growth, but the tumors with normalized vasculature 
were more sensitive to chemotherapeutic treatments (Stockmann et al. 
2008) 
 
Tie2-expressing macrophages are a subset of circulating and tumor-
infiltrating monocytes. These macrophages preferentially localize in the 
perivascular areas. Selective depletion of them decreases tumor growth 
and angiogenesis, but their elimination does not affect the recruitment 
of the TAMs into tumors suggesting that these cells form a separate 
subpopulation (De Palma et al. 2005, Venneri et al. 2007, Huang et al. 
2011). The clinical relevance of the Tie2-expressing macrophages has 
been studied only in two human cancers with contradicting results 
(Matsubara et al. 2012, Schauer et al. 2012, Goede et al. 2012). 
 
3.1.2 Granulocytes 
The presence of a large number of neutrophils in tumor correlates with 
poor prognosis in several types of human cancer (Rao et al. 2012, 
Bellocq et al. 1998, Jensen et al. 2009). Like the TAMs, neutrophils 
promote tumor angiogenesis by secreting matrix degrading MMP-9, and 
proangiogenic factors, such as VEGF-A and PROK2  (Coussens et al. 
2000, Van Coillie et al. 2001, Nozawa et al. 2006, Ardi et al. 2007, 
Shojaei et al. 2008b).  However, similar to the TAMs, neutrophils might 
have several activation states in tumors (Fridlender et al. 2009). 
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3.2 Lymphoid cells 
Adaptive immune response involves a concerted action of B cells, 
natural killer (NK) cells, DCs, helper T cells, regulatory T cells, and 
cytotoxic T cells (CTLs) generating a more specialized attack against 
foreign substances compared to innate immune reactions. The DCs are 
present in tissues as immature DCs, which have a high phagocytic 
capacity. Foreign antigens stimulate DC maturation and migration to the 
lymphoid tissues for antigen presentation. NK cells participate in the 
regulation of DC maturation and trigger apoptosis in virally infected 
cells. B cells secrete antibodies that bind to foreign antigens flagging 
them for destruction (de Visser et al 2006). Helper T cells recognize 
antigenic epitopes and secrete cytokines that activate CTLs. Activated 
CTLs secrete cytokines that trigger apoptosis in the abnormal cells. 
Helper T cells have several types of cytokine responses, such as the 
adaptive immunity promoting Th1 type response, and Th2 type 
response that inhibits adaptive immunity due to the secretion of 
immunosuppressive cytokines (Wan 2010). 
 
T and NK cell-deficient mice are susceptible to cancer development, 
whereas patients with tumors that are heavily filtrated with NK cells and 
CTLs tend to have prolonged survival times. The presence of a large 
number of regulatory T cells that suppress the activity of CTLs is 
generally associated with poor outcome in several types of cancer (Teng 
et al. 2008, Fridman et al. 2012). Regulatory T cells might also promote 
angiogenesis in some tumors (Facciabene et al. 2011). Tumor-derived 
factors, such as VEGF-A, may restrict DC maturation (Gabrilovich et 
al. 1998, Michielsen et al. 2011). Fast-growing vascular tumors contain 
more immature DCs compared to dormant avascular tumors (Curiel et 
al. 2004, Fainaru et al. 2010). 
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3.3 Mast cells 
The intratumoral mast cell number correlates with tumor vascularity in 
breast, lung and stomach cancer, as well as in breast cancer 
micrometastases (Yano et al. 1999, Ribatti et al. 2007, Dundar et al. 
2008, Ranieri et al. 2009). Mast cell-deficient mice show a low rate of 
premalignant tumor angiogenesis (Starkey et al. 1988, Coussens et al. 
1999). Mast cells are important also in the development of adenomatous 
polyps that are involved in colon and pancreatic islet cell cancer 
carcinogenesis (Soucek et al. 2007, Gounaris et al. 2007). Mast cells are 
a rich source of several proangiogenic cytokines and growth factors, 
such as VEGF-A, basic fibroblast growth factor, and tumor necrosis 
factor (Maltbyet al. 2009).  
 
3.4 Myeloid-derived suppressor cells 
Myeloid derived suppressor cells are a heterogeneous population of 
immature myeloid cells that are capable of suppressing adaptive 
immunity. Their number is often increased in cancer patients (Almand 
et al. 2001). The myeloid derived suppressor cells suppress the actions 
of the NK cells and T cells. The myeloid-derived suppressor cells 
increase tumor vascular density and vessel maturation, and decrease 
necrosis, which is likely regulated via MMP-9 (Yang et al. 2004).  
 
The typical influence of different BMDC populations on tumor growth 
are summarized below in Figure 4. 
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3.5 Fibroblasts  
Fibroblasts are an important cell type in the tumor microenvironment. 
Fibroblasts control the tissue topography by regulating ECM 
homeostasis and epithelial differentiation. The fibroblast phenotypes are 
often tissue-specific (Chang et al. 2002). In tumors, fibroblasts acquire 
an activated phenotype (Kalluri, Zeisberg 2006). The tumor fibroblasts 
might originate from several sources, such as from normal tissue 
fibroblasts, bone marrow mesenchymal stem cells, via epithelial to 
mesenchymal transition or from the ECs via endothelial to 
mesenchymal transition (Iwano et al. 2002, Direkze et al. 2004, 
Zeisberg et al. 2007, Mishra et al. 2008, Kojima et al. 2010). Fibroblasts 
may suppress anti-tumor immunity (Kraman et al. 2010). Tumor 
fibroblasts may promote the growth of epithelial tumors, such as breast 
and prostate cancers (Olumi et al. 1999, Jacobs et al. 1999). Fibroblasts 
extracted from human breast carcinomas and mixed with breast cancer 
cells increase primary tumor growth and metastasis in mice, which is 
partly mediated via secretion of the stromal-derived factor-1 (Orimo et 
al. 2005). Loss of transforming growth factor-" signaling in fibroblasts 
increases the carcinogenic potential of the adjacent epithelia 
(Bhowmick et al. 2004, Achyut et al. 2013, Franco et al. 2011).  
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The general aim of this thesis was to study the role of BMDCs in 
angiogenesis and cancer.  
 
The specific aims were: 
I    To study the BMDC contribution to the vascular endothelium 
II To study the effects of an EGFR inhibitor gefitinib on tumor 
vasculature and stromal BMDCs 
III To study prokineticins in tumor growth, angiogenesis and immune 
response 
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Original publications are referred to with their roman numerals (I, I, II). 
1. Research series 
1.1 Mice (I, II)  
Age- and sex-matched C57BL/6J and BALB/c mice (age 8 weeks, 
male) were purchased from Harlan (Harlan Laboratories, Horst, The 
Netherlands). The transgenic animals used in this thesis and their 
sources are listed in Table 1. The parabiosis experiments were done in 
collaboration with Dr. Irving Weismann’s lab, and thereby these mice 
are not included in the list below. Mice experiments were approved by 
the provincial state office of Southern Finland. 
 
Table 1. Mice strains used in the bone marrow transplantation 
experiments. 
 
Mouse line Description Source Used 
in 
CD-1/129Sv-tielcz ß-galactosidase 
under Tie1 -
promoter 
Prof. K 
Alitalo’s 
laboratory 
I 
C57BL/6-Tg(ACTB-
EGFP)1Osb/J 
Green 
fluorescent 
protein (GFP) 
under universal 
ß-actin 
promoter 
The Jackson 
Laboratory, 
Bar Harbor, 
ME 
I, II 
C57BL/6J-Kdrtm1Jrt ß-galactosidase 
under VEGFR-
2 promoter 
The Jackson 
Laboratory 
I 
129S6/B6-F1-TgN(ACTB-
DsRED.T3)Nagy 
Red fluorescent 
protein under 
universal ß -
actin promoter 
Prof. K. 
Alitalo’s 
laboratory 
I 
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1.2 Patients (III) 
The study population of paper III consisted of patients diagnosed with 
MCC in Finland from 1979 to 2004.  The patients were identified from 
the Finnish Cancer Registry and from the patient registry of the Helsinki 
University Central Hospital. The histopathological diagnoses were 
reviewed by a pathologist, and the diagnosis of MCC was considered 
confirmed when tumor morphology was compatible with MCC and 
immunostaining for cytokeratin 20 was positive, or both synaptophysin 
and chromogranin A were positive when cytokeratin 20 was not 
expressed. Tumor histology was classified according to the World 
Health Organization criteria (Sihto et al. 2009, LeBoit et al. 2006).   
 
A total of 207 patients were identified of these 109 (52,7%) were 
excluded for following reasons: paraffin embedded tumor tissue 
samples were not available (n = 37), tumor was not MCC in a 
histopathological review (n = 13), the primary tumor site was unknown 
(n = 8), clinical information was missing (n = 16), tumor tissue was not 
available for RNA extraction (n = 30), or RNA extracted from the 
tumor was not satisfactory (n = 5). The remaining 98 patients were 
included in the study. 
 
Clinical staging of the tumors was done according to the staging criteria 
by Lemos et. al (Lemos et al. 2010). The study was approved by an 
institutional review board of the Helsinki University Central Hospital. 
The permission to collect tumor tissue and clinical data for the study 
purposes was given by the Ministry of Health and Social Affairs, 
Finland. 
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2. Bone marrow transplantations (I, II) 
To prevent infections during bone marrow transplantation and the 
recovery time, the drinking water of the recipient mice (wild type 
C57BL/J or transgene negative colony siblings) was supplemented with 
antibiotics (Neomycin sulfate 1,1 g/l, Amresco; Polymyxin B sulfate 
123,8 mg/l, Gibco, Life Technologies, Carlsbad, CA). Antibiotics 
treatment was started one week before irradiation. Radiation was given 
in two fractions with a three-hour time interval between the fractions to 
yield a total lethal dosage of 9.2 Gy. On the following day after 
irradiation, the donor mouse was sacrificed with cervical dislocation, 
the hind limbs of the donor mouse were extracted, and the femurs and 
the tibias were flushed with Dulbecco’s modified Eagle’s medium 
(DMEM, Life Technologies) supplemented with 2mM L-Glutamin and 
PenStrep (penicillin, 100 U/ml, streptomycin 100 µl/mL; Sigma-
Aldrich, St. Louis, MI). Subsequently, the flushed bone marrow cells 
were injected to the recipient mice tail vein with a 29G insulin needle. 
After the transplantation, the recipient mice were let to recover for 5 
weeks before use in further experiments. The bone marrow 
reconstitution of the chimeric GFP or red fluorescent protein mice was 
monitored by analyzing the peripheral blood cells with flow cytometry. 
The donor mice that were used in the transplantation experiments are 
summarized in Table 1. 
 
3. Bone marrow cell mobilization experiments (I) 
The mouse B16-F1 melanoma cell line (ATCC, Manassas, VA) was 
maintained in DMEM supplemented with 2mM L-Glutamin, PenStrep, 
and 10% fetal bovine serum (Promocell, Heidelberg, Germany). To 
study mobilization, 2 x106 cells were injected subcutaneously into the 
dorsal hind limb of the mice (C57BL/6J, n = 12). Blood samples were 
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collected from the mice via the tail vein to Na-heparin capillaries (Heinz 
Herenz, Hamburg, Germany) and mixed with the same amount of 0.5M 
EDTA. The blood sampling days were 0, 3, 5, 7, 11, 14 and 17. The 
largest diameters of the tumors that had developed were measured on 
every blood-sampling day.  
 
To study VEGF-A polypeptide mediated BMDC mobilization, 
recombinant murine VEGF164 (Biosource, Life technologies) was 
given daily intraperitoneally for 5 days (10 µg/mouse/day; n = 6). A 
control group of mice received the same volume (100 µl) of 0.1% BSA 
(n = 6). The peripheral blood of the mice from VEGF-injected and the 
control groups was sampled on days 0, 3, 5 and 7. 
 
Adenoviruses were received from the laboratory of Prof. Seppo Ylä-
Herttuala (the Department of Molecular Medicine, University of 
Kuopio, Finland). Adenoviruses encoding either LacZ or murine 
VEGF-A were administered via the tail vein into C57BL/6J and 
BALB/c mice (n = 6). The viral particle doses were 1 x109 PFU for the 
BALB/c mice and 1x108 PFU for the C57BL/6J mice. In the control 
group, the mice were injected with 100 µl of PBS (n = 6). Peripheral 
blood samples were collected on days 0, 3, 5, 7, 14 and 21. 
 
4. Flow cytometry (I) 
The total number of white blood cells was first quantified by a 
Neubauer hemacytometer. Before cell counting, red blood cells were 
lysed with 2% acetic acid. For the flow cytometry analysis, the collected 
blood was lysed with a PharmLyse lysis buffer to remove the red blood 
cells (BD Biociences, San Jose, CA). Next, the cells were incubated 
with an anti-mouse CD16/CD32 blocker (BD Biosciences) to reduce 
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FcII/III receptor-mediated antibody binding, and the cells were stained 
for 30 min at +4ºC with a fluorescein isotiocyanate -conjugated anti-
mouse Cd11b antibody or anti-mouse Sca-1 antibody, a phycoerythrin-
conjugated VEGFR-2 antibody, and allophycocyanin-conjugated anti-
mouse CD117 antibody. The correct detection of VEGFR-2 positive 
cells was controlled using a murine EC line (MS-1). After the staining, 
the cells were washed with PBS containing 1% fetal serum (Promocell, 
Heidelberg, Germany) and 0.1% sodium azide (Sigma-aldrich), and 
fixed with 2% paraformaldehyde (Sigma-Aldrich). All antibodies were 
purchased from BD Biosciences  
 
The samples were analyzed with a FACSAria flow cytometer (BD 
Biosciences). Positively staining cells were identified by comparing the 
staining with equivalent IgG isotype-stained control cells. Dead cells 
and debris were gated out based on the forward and side light scatter. 
Before the analysis, the fluorochrome spectral overlaps were 
compensated automatically using the FACSDiva software 4.1.2.  
 
5. Mouse angiogenesis models 
5.1 B16 melanoma tumor model (I, II) 
To study tumor angiogenesis, chimeric mice having GFP-positive bone 
marrow were given subcutaneous injection of B16-F1 melanoma cells 
(2 x106 cells in 20 µL of PBS), and the tumors were allowed to grow for 
7-21 days. The mice were sacrificed, and tumor tissue was collected for 
immunohistochemical analyses. Depending on the site of the injection, 
the tissues were either processed as whole mounts or as frozen sections. 
Ear tumors were examined with whole mount stainings, whereas tumors 
grown in the dorsal hind limbs were analyzed as frozen sections. 
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5.2 Matrigel assay for angiogenesis (I) 
Two matrigel plugs (400 µL/injection, Basement membrane matrixTM; 
BD Biosciences) supplemented with recombinant murine VEGF164 
(100ng/mL; R&D Systems Inc, Minneapolis, MN) were injected to the 
ventral side of the mouse. The exact injection location was close to the 
ventral midline near the groin area. The plugs were removed for tissue 
analyses at several time points. The majority of the plugs were analyzed 
with whole mount stainings 7 or 14 days after the injection, but shorter 
and longer time periods than this were also investigated (ranging from 1 
day to 6 months). The removed plugs were mostly stained and analyzed 
as whole mounts, but some of the beta-galactosidase-stained whole 
mounts were embedded to paraffin and cut to sections.  
 
5.3 Adenoviral VEGF-A ear injections (I) 
Chimeric mice were injected subcutaneously in the ear with 
AdVEGF164 (2 x108 PFU/injection/ear). After 14 days, the mice were 
sacrificed, and the ears were collected for immunohistochemistry. The 
tissues were either processed as whole mounts or frozen for sectioning. 
 
6. Immunohistochemistry 
The primary antibodies used in immunohistochemical stainings are 
summarized in Table 2. 
6.1 Whole mount immunohistochemistry (I) 
Tissue pieces were fixed with fresh 4% paraformaldehyde for 1h at 
room temperature (RT). From ear samples autofluorescent cartilage and 
excess tumor tissue were removed before fixation to enable flat 
mounting. After fixation, the tissue pieces were thoroughly washed for 
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at least 2 hours with several changes of PBS containing 0.3% Triton-X 
(Sigma-Aldrich). The samples were blocked for 1 hour with 5% goat 
serum (Vector laboratories, Burlingame, CA) and 0.2% bovine serum 
albumin (Sigma-Aldrich) diluted in the washing solution. After 
blocking, the primary antibodies were added to the blocking solution 
and incubated for two days at RT. The samples were then washed and 
incubated with the fluorochrome-conjugated secondary antibodies 
overnight at RT. The secondary antibodies used in the stainings were 
Alexa488 anti-rat, Alexa594 anti-rat, Alexa594 anti-rabbit, Alexa633 
anti-rat, and Alexa633 anti-rabbit IgG (Molecular Probes, Life 
Technologies). After detection, the samples were washed and briefly 
post-fixed with 4% paraformaldehyde. DAPI staining (5 µg/mL, Sigma-
Aldrich) to detect nuclei was performed during the final washes. The 
mounting procedure depended on the tissue type processed; the plugs 
were sliced with a scalpel and the ears were flattened before placing 
them into an anti-fading medium (Vectashield, Vector laboratories). 
Part of the samples was stained with an anti-GFP-Alexa488 antibody to 
confirm that the GFP signal in the BMDCs is correctly detected 
(Molecular Probes, Life Technologies).  
 
6.2 Immunohistochemistry of frozen sections (I, II) 
The samples that contained fluorescent markers were first fixed for 1h 
with fresh 2% paraformaldehyde and then incubated in fresh 20% 
sucrose in PBS for overnight at +4ºC. The samples that had proper 
sucrose penetration sank to the bottom of the tube. After this additional 
cryopreservation step, the samples were frozen on dry ice embedded in 
the O.C.T compound (Tissue-Tek, Sakura Finetek Europe B.V, AV 
Alphen aan den Rijn, The Netherlands). The sections were fixed with 
ice-cold acetone for 10 min and washed with PBS before blocking with 
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5% normal goat serum (Vector laboratories) for 30 min at RT. The 
primary antibodies were diluted in a blocking solution and incubated 
overnight at +4ºC. The primary antibodies were detected with the 
fluorochrome-conjugated secondary antibodies listed earlier. 
 
6.3 Immunohistochemistry of paraffin sections (III) 
The stainings were done for slides cut from a MCC tumor tissue 
microarray. Paraffin was removed with xylene, and the sections were 
rehydrated through changes in a decreasing ethanol gradient. The 
samples were then washed in H2O, and antigen retrieval was done in a 
0.01M sodium citrate buffer, pH 6, either in a water bath +98ºC for 20-
40 min (prokineticin stainings) or in an autoclave (stainings for human 
CD31). After antigen retrieval, the samples were let to cool down, 
washed, and nonspecific staining was blocked with 1% H202. The 
samples were then blocked with a universal blocking diluent and 
incubated with the primary antibodies overnight at +4ºC. Subsequently, 
the primary antibodies were detected with horse radish peroxidase-
conjugated secondary antibodies using a Histofine anti-rabbit simple 
stain MAX PO® kit for prokineticin antibodies (Nichirei Biosciences 
Inc, Tokyo, Japan). Human CD31 was detected with a Vectastain elite 
goat kit (Vector laboratories).  
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Table 2. The primary antibodies used for immunohistochemistry 
stainings 
 
Protein IHC method Dilutio
n 
Manufacturer Used 
in 
CD31 IHC-P 1:100 Santa Cruz 
Biotechnology 
inc. 
III 
CD31 IHC-Fr, IHC-
WM 
1:500 BD Bioscience I, II 
CD105 IHC-Fr, IHC-
WM 
1:100 BD Bioscience I 
NG-2 IHC-Fr 1:200 Chemicon II 
PROK1 IHC-P 1:200 Covalab III 
PROK2 IHC-P 1:200 Covalab III 
PROKR1 IHC-P 1:300 Lifespan 
Biosciences 
III 
PROKR2 IHC-P 1:300 Lifespan 
Biosciences 
III 
!-SMA  IHC-Fr 1:1000 Sigma-Aldrich II 
VEGFR-2 IHC-Fr, IHC-
WM 
1:50 BD Bioscience I 
vWF IHC-Fr, IHC-
WM 
1:700 DAKO I 
Abbreviations: IHC=immunohistochemistry, IHC-Fr=immunohistochemistry 
of frozen sections, IHC-P=immunohistochemistry of paraffin sections, IHC-
WM=whole mount stainings 
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6.4 Other staining methods (I) 
Rhodamine-labeled Ricinus Communis-lectin (Vector laboratories) was 
injected as a single 500 µg dose to the tail vein and let to circulate 5-15 
min to bind to the functional blood vasculature before perfusion fixation 
with 4% paraformaldehyde. Then the tissue was extracted and 
processed for frozen sections. 
 
ß-galactosidase staining was performed for samples containing cells that 
had lacZ-gene under the endothelial promoter (Tie1 or VEGF-R2). The 
matrigel plugs and subcutaneous ear tumors were collected in PBS and 
fixed for 30 min at RT in a solution containing 0.2% glutaraldehyde in a 
0.1M phosphate buffer, pH 7.3, supplemented with 0.5mM ethylene 
glycol tetraacetic acid and 2mM MgCl2. The samples were then washed 
three times with 0.1M phosphate buffer containing 2 mM MgCl2, 0.01% 
deoxycholic acid sodium salt, and 0.02% Nonidet P40 for 15 min in 
total. Then the samples were stained with X-gal (1 mg/mL) diluted with 
a wash buffer containing 2.12 mg/mL potassium ferrosyanide and 1.64 
mg/mL potassium ferrisyanide at +37ºC for overnight. All reagents 
were purchased from Sigma-Aldrich. After staining, the samples were 
washed with a wash buffer overnight at +4ºC and fixed overnight at 
+4ºC. The samples were analyzed using a Leica MZFLIII 
stereomicroscope with 12.5x magnification and photographed with a 
Leica DFC480 camera (Leica Microsystems, Heidelberg GmbH, 
Mannheim, Germany). 
 
To detect ß-gal–positive cells in a chimeric bone marrow, the bone 
marrow cells were flushed from the hind limb bones according to bone 
marrow transplantation protocol described in the methods section 2. 
Next, 1.5 x106 cells were suspended in 350 µL of Matrigel (BD 
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Biosciences) and let to solidify for 1h at +37ºC. The staining for ß-
galactosidase was done as described above. ß-gal positive cells were 
scored under a Zeiss Axiovert 135 inverted epifluorescence microsope 
(Carl Zeiss, Göttingen, Germany) using LD Acroplan objectives 20x 
(numeric aperture, 0.4), 40x (numeric aperture, 0.6 with a correction 
collar) and 63x (numeric aperture, 0.75 with a correction collar), and 
photographed with a Hamamatsu digital camera (Hamamatsu, Japan). 
 
Some of the ß-gal stained plugs and tumor samples were analyzed as 
sections. The ß-gal-stained samples were first dehydrated through 
increasing concentrations of ethanol, cleared with xylene, and 
embedded in paraffin. The sections were cut with a microtome and 
mounted onto Superfrost+ microscope slides (Menzel-Gläser, 
Braunschweig, Germany) and dried overnight at +37ºC. Before 
analysis, the samples were deparaffinized, rehydrated, and stained using 
a Certistain Nuclear fast red stain for 2.5 min (Merck, Darmstadt, 
Germany).  
 
6. Tissue analyses 
6.1 Protein co-localization analyses (I, II) 
Four colour-stained whole mounts and frozen sections (DAPI to stain 
the nuclei, GFP from the bone marrow cells, Alexa594 CD31, CD105 
or VEGFR-2, and Alexa633 vWF) were analyzed with a Zeiss LSM510 
confocal microscope (software version 3.2, Carl Zeiss, Göttingen, 
Germany). The sequential scans were taken in a frame mode using 
mostly a 40x (numeric aperture, 1.3) Plan Neofluar oil objective. A 
single 2D scan had an optical slice thickness  of 1.0 µm. The gain 
settings were carefully adjusted using control stainings to prevent 
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channel leakage between the Alexa594 and Alexa633 stainings. In 
addition, the samples were analyzed and photographed with an 
Axioplan 2 immunofluorescence microscope using 20x (numeric 
aperture, 0.5) and 40x (numeric aperture, 0.75) Plan Neofluar 
objectives, an Axiocam Hrc camera, and an Axiovision 4.3 software 
(Carl Zeiss). 
 
6.2 Microvessel density analyses (II, III) 
Microvessel density was analyzed by calculating CD31-positive (studies 
II and III) and smooth muscle actin and NG-2-positive (study II) 
vascular structures per one high power field of the microscope 
(Axiovert 200M with LSM510 Meta; Carl Zeiss in study II, and an 
Olympus BX50 microscope, Olympus, Center Valley, PA, in study III). 
The vessel diameter-based classification (the lumen size <50 µm vs. 
>50 µm, study II) was based on the maximum vessel diameter. The 
number of BMDCs was evaluated by counting the number of GFP-
positive cells near each vessel (study II).  
 
6.3 Immunohistochemical scorings (III) 
The staining intensity of PROK1, PROK2, PROKR1, and PROKR2 was 
scored from tissue microarrays semi-quantitatively using 200x 
magnification (an Olympus BX50 microscope, Olympus). The stainings 
were classified negative (0), moderately positive (+, when the tumor 
cells showed light or moderate staining intensity), or strongly positive 
(++, when the tumor cells show strong staining intensity). 
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7. Quantitative PCR (III) 
RNA was isolated from formalin-fixed paraffin-embedded (FFPE) 
tissue samples. From each tumor, three sections were cut and then lysed 
overnight at +56ºC with a MoleStripsTM RNA Tissue kit (MGK30.101-
101, Mole Genetics AS, Lysaker, Norway) lysis buffer supplemented 
with proteinase K (10µg/µL, Roche, Basel, Switzerland). After the 
lysis, the samples were warmed at 95ºC for 5 min and centrifuged at the 
maximum speed of 13,000 rpm for 1 min. This step created a solid 
paraffin layer on top of the lysate. The lysate was transferred to a new 
tube, and RNA was extracted using MoleStripsTM and the GeneMole® 
automated nucleic acid extraction instrument (Mole Genetics AS). The 
RNA concentration of the samples was determined with a Nanodrop 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA). The 
typical RNA yields varied between 4 to 68 ng/µL of RNA. 
 
Approximately 60-200 ng of the extracted RNA was first reverse 
transcribed to cDNA in 20 µl using a Superscript VILOTM cDNA 
synthesis kit. The expression level of PROK1 and PROK2 was 
determined relative to the TATA-box-binding-protein (TBP, GenBank 
#M55654) in the same samples. PROK1 expression was measured using 
a forward primer 5’-CCACGCGAGTCTCAATCA-3’ and a reverse 5’-
ACTGGACATCCCGCTCAC-3’ primer, and a locked nucleic acid 
hydrolysis probe 63. PROK2 was measured using primers 5’-
AAGCAAAAGGAAAAAGGAGGTT-3’ (forward), 5’-
CAGACATGGGCAAGTGTGA-3’ (reverse) and the locked nucleic 
acid probe 88. TBP expression was measured using a Universal 
ProbeLibrary human TBP gene assay (Roche Diagnostics, GmbH). The 
primers and probes were designed with a Probefinder software at the 
Universal ProbeLibrary Assay Design Center (Roche Diagnostics, 
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GmbH). The measurements were done with Lightcycler Probes Master 
reagents and with a Lightcycler 480 instrument (Roche Diagnostics, 
Mannheim, Germany). The reaction mixture contained 1x ProbeMaster, 
100nM probe, 200 nM primers, and 2 µl of the template cDNA. All 
samples were run in triplicates. RNA derived from a histologically 
normal testis and peripheral blood leukocyte RNA was used as positive 
controls for PROK1 and PROK2 assays, respectively. Before analysis, a 
standard series was measured to determine the real amplification 
efficiency of the constructs. To compare the values between different 
measurements, an inter-assay calibrator sample was used on each plate. 
The relative expression was calculated with the E-method software 
(Roche Diagnostics). The reaction mixture was run on a 2.5% agarose 
gel to verify that the PCR reaction had yielded a single amplicon (84 nt 
for PROK1, 64 nt for PROK2). 
 
 8. Statistical analyses (II and III) 
The statistical calculations were done with an SPSS statistics 20 (IBM, 
Armonk, NY). Frequency distributions were evaluated with the #2 test 
or the Fischer’s exact test (III). The distributions of continuous variables 
between groups were examined with the Student’s t-test (II), the Mann-
Whitney’s U-test (III) or the Kruskal-Wallis test (III), and continuous 
variables were analyzed with Spearman’s rank correlation (III).  
 
Survival was estimated with the Kaplan-Meier method (III). Overall 
survival was calculated from the date of the diagnosis to the date of 
death censoring those patients still alive on the last day of follow-up. 
MCC-specific survival was calculated from the date of the diagnosis to 
the date of death caused by MCC, which was based on clinical 
judgement or autopsy evidence. Patients who were alive or who died 
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from other causes than MCC or from an unknown cause were censored. 
The hazard ratios and their confidence intervals were calculated with an 
unadjusted Cox’s proportional hazards model.  
 
 +
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1. BMDC mobilization in response to VEGF-A and B16 melanoma 
tumors (I) 
It has been suggested that VEGF-A mobilize EPCs from the bone 
marrow (Asahara et al. 1999b, Hattori et al. 2001a, Moore et al. 2001). 
EPC mobilization was analyzed using the mouse VEGF164 isoform, and 
mice were injected either with the VEGF164 polypeptide or adenoviral 
vectors expressing either VEGF164 or LacZ. Blood samples were 
collected at several time points and analyzed with flow cytometry. The 
putative EPCs were considered to consist of either VEGFR-2+ or 
VEGFR-2+/Cd11b- circulating cells as described earlier (Asahara et al. 
1997, Asahara et al. 1999b, Hattori et al. 2001a). The VEGF164 
polypeptide did not result in mobilization of the total BMDCs or the 
VEGFR-2+ or VEGFR-2+/Cd11b- cell populations. When adenoviral 
VEGF was used, a transient mobilization of the total BMDC counts was 
observed five to seven days after vector administration, but this rise was 
likely unspecific, as a similar peak in the respective cell counts was 
observed also in mice that received adenoviral lacZ. PBS was injected 
to the control group. 
 
To study the effects of implanted tumors on BMDC and EPC 
mobilization, mice were injected either with PBS or B16 tumor cells 
that generate subcutaneous tumors, and the numbers of circulating 
VEGFR-2+ or VEGFR-2/CD11b- cells were measured from the 
peripheral blood. The tumors promoted mobilization of BMDCs from 
the bone marrow when determined by counting the total BMDCs. The 
mobilization was most evident between days 11-14 from the date of 
B16 cell injection when the subcutaneous tumors grew the fastest. 
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However, the numbers of circulating VEGFR-2+ cells remained 
constant in response to tumor growth representing 1-2 % of the total 
number of peripheral blood BMDCs. 
 
2. BMDC contribution to endothelium in vivo (I, II) 
BMDC endothelial differentiation was studied with several 
experimental approaches. In one set of experiments, GFP-tagged 
BMDCs were transferred to recipient mice. This generated chimeric 
animals that were studied for angiogenesis using three different models, 
the matrigel plugs, subcutaneous B16 tumors, and subcutaneous 
adenoviral VEGF-A injections. From these models, the matrigel plug 
model was the most convenient one for assessing the rate of 
angiogenesis due to the lack of pre-existing vasculature within the plug. 
The newly formed vasculature was detected with double labeling of 
vWF combined either with VEGFR-2, CD31, or CD105. Mouse ears 
were injected with adenoviral VEGF-A, and B16 tumors were analyzed 
both as frozen sections and from whole mounts. In the analyses, 
BMDCs did not express the endothelial markers and did not localize to 
luminal space of the vascular wall. A small subset of BMDCs was 
found in very close vicinity to the vascular ECs. The majority of the 
BMDCs were detected either close to the vascular regions or were 
found scattered around the stroma. In a time series, BMDCs could be 
observed as early as one day after implantation of the matrigel plugs, 
and the majority of these cells were CD11b –positive representing cells 
of myeloid lineage.  
 
The result was the same when matrigel plugs and B16 melanoma 
tumors were analyzed with genetic models where the mice expressed a 
ß-galactosidase marker gene either under the VEGFR-2 or Tie1 
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promoter. The matrigel plugs and the B16 tumors were implanted both 
to transgenic mice and to bone marrow chimeras. BMDCs showing 
vascular morphology were absent in the samples of the bone marrow 
chimeras, whereas marker gene positive vasculature was detected in the 
transgenic mice. The matrigel plug analysis was conducted both from 
tissue sections and from whole tissue mounts.  
 
Finally, BMDC differentiation was studied also without myeloablation. 
APCmin mice, which spontaneously develop adenomas of the small 
intestine, were surgically joined with mice expressing GFP fluorescent 
protein in all tissues. Since these two mice strains shared circulation, 
approximately 50% of the BMDCs present in the peripheral blood 
during tumor development are GFP-positive. The blood chimerism was 
confirmed by examining the immune cell infiltration of the Payer’s 
patches from intestinal samples. Examination of the adenomas with 
several EC markers (CD31, CD105, VEGFR-2, and vWF) did not 
provide any new evidence that the bone marrow would be a source of 
the tumor blood vessel endothelium. Occasional double positive cells to 
GFP and one of the EC markers were detected, but these cells did not 
show vascular morphology and, thus, likely represented hematopoietic 
cells known to express these markers. 
 
3. Effects of EGFR inhibition on tumor stroma (II) 
EGFR might regulate the recruitment of perivascular cells (Iivanainen et 
al. 2003). To address this, the vascular effects of the EGFR inhibitor 
gefitinib were analyzed in vivo using the mouse subcutaneous The B16 
melanoma tumor model and GFP bone marrow transplantation like in 
study I. B16 melanoma tumor model was chosen, as EGFR expression 
was not found at the mRNA or protein level in B16 cells, and B16 cells 
 56 
were also relatively resistant to gefitinib treatment in a clonogenic 
growth assay. This suggested that angiogenesis could be studied in the 
B16 tumor model without directly affecting the tumor cells by gefitinib 
treatment. 
 
C57BL/6J mice transplanted with syngeneic GFP-positive bone marrow 
were injected with B16 melanoma cells, and the tumors were let to grow 
for 13-15 days. Gefitinib or a buffer control treatment was started 
before the tumors reached a size of 100 mm3. Gefitinib or buffer was 
given daily orally and continued for a maximum of 7 days. This 
duration of gefitinib treatment resulted in only a moderate and 
statistically non-significant reduction in the tumor volumes as compared 
with the control mice (p = 0.12). Tumor samples were collected and 
processed into frozen sections, stained with CD31, SMA and NG-2 
antibodies, and analyzed using a confocal microscope. 
 
The microvascular density was scored from the sections by calculating 
the number of CD31-positive vessels from the vascular hot spot regions 
of the tumors per 1 high power field of the microscope. Three tumor 
regions were analyzed from each mouse (a total of 15 regions from 5 
mice). There was a small but statistically non-significant increase in the 
microvascular density of the tumors, but when microvessel counting 
was done separately for small and large microvessels (the lumen 
diameter <50 µm vs. >50 µm; 5 tumor regions/mouse, a total of 25 
regions), gefitinib treatment increased the microvacular density of the 
small vessels in the tumors (p = 0.04).  
 
NG-2 is a molecular marker for the early pericytes, while the smooth 
muscle actin is typically expressed in the fully differentiated pericytes 
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or smooth muscle cells (Ozerdem et al. 2001). Gefitinib affected neither 
the number of smooth muscle actin-positive vessels in the tumors nor 
the ratio of smooth muscle actin-positive vessels to CD31-positive 
vessels. Similarly, no significant change in the numbers of microvessels 
was observed when the NG-2-positive vessels were counted. However, 
when the vessel diameter was taken into account, a significant reduction 
in the number and ratio of NG-2-positive pericytes to CD31-positive 
vessels was observed with the subset of small vessels (<50 µm, p = 
0.004), but not in the subset of larger vessels (p = 0.49), suggesting that 
gefitinib reduced the numbers of pericytes in newly formed small 
microvessels.  
 
Finally, the effect of gefitinib on the stromal BMDC was studied. Ten 
randomly selected tumor regions were analyzed from five mice (a total 
of 50 regions). BMDCs were found in tumor microvessel lumens and in 
the perivascular regions close to the endothelial layer in control mice. 
Gefitinib treatment did not affect the numbers of the BMDCs in the 
lumens (p = 0.33), but caused a significant reduction in the perivascular 
BMDC counts (p = 0.01). Colocalization analyses revealed that only 
few BMDCs had immunoreactivity for CD31, smooth muscle actin, or 
NG2, and gefitinib did not have a significant effect on the numbers of 
such cells (p = 0.09, 0.16 and 0.15, respectively).  
 
4. Prokineticins in human virus-associated cancer (III)  
It has been suggested that PROK2 mediate BMDC-dependent 
angiogenesis in tumors (Shojaei et al. 2007b). It is not known whether 
PROK2 and its other family members contribute to the angiogenesis 
and the immune response in human tumors. The clinical correlates of 
the prokineticin protein family members were studied in MCC. MCC is 
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a rare human skin cancer that may have viral origin (Feng et al. 2008), 
and the immune system has likely significant influence on its onset and 
progression (Sihto et al. 2012). The study population consisted of 98 
MCC patients diagnosed in Finland between 1979 and 2004. 
 
Immunohistochemical analysis of tumor tissue microarrays revealed 
that expression of PROK2 and PROKR2 was more frequently present in 
cancer cells of the primary tumors than PROK1 or PROKR1 expression. 
PROK2 expression was found in 45.5% of the MCCs (41/90) and 
PROKR2 in 51.1% (47/92) of the tumors, while PROK1 was expressed 
in 22.9% (21/92) and PROKR1 in 9.1% (8/88) of the cancers. Most 
tumors showed weak or moderate expression levels of these proteins in 
tumor cells (+), and high expression (++) was uncommon.  
 
PROKR2 expression in tumor cells was associated with the presence of 
MCPyV DNA in tumor. From 60 MCPyV DNA-positive MCCs, 36 
(60%) expressed PROKR2 compared to 5 (25%) of the 20 cancers that 
were MCPyV DNA-negative (p = 0.007). Also the MCPyV large T 
antigen was frequently expressed in PROKR2-positive cancers (36 out 
of the 46 PROKR2-positive tumors compared to 22 out of the 44 
PROKR2-negative cancers, p = 0.005). MCPyV-positive MCCs 
frequently express the retinoblastoma protein (Sihto et al. 2011). 
PROKR2-positive cancers expressed the retinoblastoma protein more 
frequently than PROKR2-negative cancers (36 of the 61 MCCs that 
expressed Rb expressed also PROKR2 compared to only 10 out of the 
29 Rb-negative MCCs, p = 0.03). Tumor cell expression of PROK1, 
PROK2 or PROKR1 was not associated with the presence of MCPyV 
DNA or viral large T antigen expression in tumor. 
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Expression of the prokineticin ligands and receptors in tumor cells was 
associated with certain subsets of tumor infiltrating leukocytes. 
Different tumor infiltrating subsets were analyzed from whole tumor 
sections by counting the numbers of intratumoral leukocytes from three 
high power fields of the microscope (Sihto et al. 2012). Tumor cell 
PROK1 expression tended to be associated with a higher than the 
median number (5.3 cells/high power field) of CD68+ macrophages (p 
= 0.054), PROK2 expression with a higher than the median number 
(3.3/high power field) of CD8+ CTLs (p = 0.030), and tended to be 
associated with a higher than the median (3.7/high power field) number 
of CD163+ macrophages (p = 0.062). PROKR2 expression was 
associated with a higher than the median (4.7/high power field) number 
of CD3+ T lymphocytes  (p = 0.055) and small CD16+ cells 
(representing mostly NK cells) (p = 0.001). Prokineticin ligands or the 
receptors did not associate with tumor infiltrating helper T cell (CD4+) 
or regulatory T cell (FoxP3+) counts (p >0.10 for each comparison). 
 
Tumor PROK1 and PROK2 mRNA content was measured with qPCR 
from whole tumor sections. Most MCCs (76 out of 98) did not contain 
detectable PROK1 mRNA and were classified as PROK1 mRNA-
negative or –positive, whereas all tumors contained detectable PROK2 
mRNA, the target gene (PROK2) to the reference gene (TBP) ratio 
ranging from 0.02 to 4.02 (median, 0.571). A higher than the median 
tumor PROK2 mRNA content was significantly associated with a lower 
than the median tumor cell proliferation rate (as assessed with the Ki-67 
staining), presence of MCPyV DNA, expression of the viral large T 
antigen protein and retinoblastoma protein. The presence of PROK1 
mRNA in tumor was associated with absence of MCPyV DNA, and 
absence of large T antigen and retinoblastoma protein expression (all p-
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values < 0.05). Furthermore, higher than median PROK2 content tended 
to associate with the absence of p53 expression (p = 0.087), whereas 
presence of PROK1 expression tended to associate with p53 expression 
(p = 0.056). The PROK2 mRNA content was associated with a higher 
than the median number of intratumoral CD68+ cells (p = 0.031) and 
CD163+ macrophages (p = 0.015). Similar associations were not found 
between PROK1 mRNA and the tumor infiltrating leukocyte subsets. 
 
Intratumoral vascular density was analyzed, and it ranged from 0 up to 
27.5 vessels/high power field (median 6.5). Tumor PROK1 or PROK2 
mRNA contents were not associated with tumor microvascular density 
in the MCCs regardless of whether the microvascular density and 
PROK1 and PROK2 mRNA contents were studied as continuous 
variables or as categorized variables using the medians as the cut-offs (p 
>0.10 for all comparisons). In immunohistochemical examination, 
PROKR1 or PROKR2 expression was not detected in the MCC vascular 
endothelium. 
 
Patients with a higher than median PROK2 mRNA content in MCC had 
more favorable overall survival compared to patients whose tumor 
contained less PROK2 mRNA (hazard ratio [HR] 0.53, 95% CI 0.34-
0.84; p = 0.005) as well as more favorable MCC-specific survival (HR 
0.42, 95% CI 0.19-0.97; p = 0.042). Presence of PROK1 mRNA in the 
tumor, in turn, tended to be associated with unfavorable overall survival 
(HR 1.61, 95% CI 0.99-2.79; p = 0.052). Prokineticin protein 
expression in tumor cells did not associate with survival (p >0.10 in 
each analysis).  
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The independence of PROK1 and PROK2 mRNA contents as 
prognostic factors was tested with a Cox multivariable model. Factors 
that were significantly associated with survival in a univariate survival 
analysis were tested in the model together with PROK1 (present vs. 
absent) and PROK2 (< median vs. > median) mRNA content. Other 
factors were age (as continuous variable), tumor stage (1, 2 vs. 3, four 
patients with distant metastases were excluded), presence of MCPyV 
DNA in tumor (present vs. absent), and tumor CD3-positive T cell 
count (< median vs. > median). Analysis showed that neither PROK1 
(HR 0.77, 95% Cl 0.38-1.59, P = 0.48) or PROK2 (HR 0.59, 95% Cl 
0.31-1.11, P = 0.104) are independent prognostic factors whereas tumor 
stage (HR 3.46, 95% Cl 1.58-7.58, P = 0.002), age (HR 1.05, 95% 1.02-
1.09, P < 0.001), presence of MCPyV in tumor (HR 0.54, 95% Cl 0.30-
0.95, P= 0.033), and CD3 cell count (HR 0.53, 95% Cl 0.30-0.92, P = 
0.012) independently influence the overall survival. 
+
 +
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1. Bone marrow as a source of the endothelium 
It has been suggested that BMDCs and the putative EPCs are mobilized 
from the bone marrow in response to the major angiogenic growth 
factor VEGF-A (Moore et al. 2001, Asahara et al. 1999b, Hattori et al. 
2001a). However, our data did not support the view that VEGF-A 
would be a mobilizing factor for the BMDCs or EPCs, as no increase 
was observed in the total white blood cell counts or in VEGFR-2+ cells 
in response to VEGF-A polypeptide or adenoviral VEGF164 injection. 
Hattori et al. and Moore et al. analyzed VEGF-A -induced mobilization 
in an immunodeficient mouse strain, and human version of adenoviral 
VEGF-A was administered in these experiments, which may explain the 
differences in findings. On the other hand, Asahara and colleagues 
conducted their VEGF-A polypeptide mobilization experiment in the 
same mouse strain but recombinant human VEGF-A was used in their 
study and the blood pre-treatment strategy was also different from our 
study (Asahara et al. 1999b). However, VEGF-A-neutralizing antibody 
inhibited the mobilization of BMDCs in their experiments, and 
therefore the differences in the pretreatment strategies do not explain 
the discrepancy in the results. In our experiments, the levels of the 
circulating VEGFR-2+ cells remained constant also when mice were 
implanted with the B16 tumors, whereas the total circulating BMDC 
counts showed a significant increase during the time of the fastest tumor 
growth.  
 
Yet, Matrigel plugs supplemented with VEGF-A and skin tissue 
injected with adenoviral VEGF-A showed abundant BMDC infiltrates 
in our experiments. Lewis lung carcinoma cells overexpressing mouse 
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VEGF164 implanted into mice recruit a dense inflammatory cell infiltrate 
(Wickersheim et al. 2009). Grunewald et al. showed in a conditional 
mouse model that induction of VEGF-A expression either in the normal 
myocardium or the liver leads to massive infiltration of circulating 
myeloid BMDCs (Grunewald et al. 2006). A significant increase in the 
circulating white blood cell counts was observed when VEGF-A was 
induced in liver, but not when it was induced in the myocardium. This 
may implicate that the circulating levels of VEGF-A originating from 
heart were lower. However, the circulating BMDCs accumulated in 
both organs upon VEGF-A induction, supporting the view that VEGF-A 
has a pronounced role in BMDC recruitment, whereas systemic 
mobilization of the white blood cells is mostly stimulated by other 
factors, such as the granulocyte colony stimulating factor or the stromal 
derived factor-1 (Socinski et al. 1988, Hattori et al. 2001b).  
 
According to some studies VEGF-A might promote BMDC 
differentiation to ECs in situ (Young et al. 2002, Li et al. 2006), but it 
was not observed in this study. Two hypotheses can be considered to 
explain the different results obtained. There are likely differences in the 
angiogenesis models and mouse strains used in the experiments. 
Angiogenic response may vary between different mouse strains, and the 
C57BL/6J strain that was used in most experiments belongs to those 
mouse strains that respond at a relatively low level upon VEGF-A 
stimulation (Shaked et al. 2005). On the other hand, there may be 
important differences in the cell detection methods used. For example, 
Young et al. and Li et al.  (Li et al. 2006, Young et al. 2002)  did the 
cell co-localization analyses only on tissue sections and did not apply 
high-resolution imaging methods, which are necessary when conducting 
colocalization analyses for the vascular wall that has 2 cell populations 
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at a very close proximity. In some of the early studies, high percentages 
of BMDC vascular incorporation may be due to the usage of 
conventional light microscopy and ß-galactosidase tagging, which may 
have led to overestimation of bone marrow-derived endothelium 
(Garcia-Barros et al. 2003, Lyden et al. 2001) . 
 
In this study, the analyses were done both from tissue sections and 
whole tissue mounts, tissues were stained with several EC markers, and 
also higher resolution confocal microscopy was used. Sections are 
useful in providing a clear view to deep tissues, since a single thin plane 
is analyzed each time, but on the other hand freezing may distort the 
vascular morphology. Whole mounts are more laborious to stain and to 
analyze, and the signal intensity may be limited by the poor deep tissue 
penetration of light, but on the other hand the whole tissue mounts may 
provide a better view on the intact angiogenic vasculature in vivo. When 
these staining approaches are combined using genetic tagging with 
fluorescent markers, strict morphological criteria, multiple EC marker 
stainings, and high resolution imaging, reliable observations about the 
BMDC contribution to the endothelium can be made. 
 
Wickersheim et al. used a similar type of imaging approach and 
analyzed thick frozen sections from several tumor types with 
multichannel confocal microscopy that was followed by 3-dimensional 
reconstructions. In line with our results, the authors showed with several 
tumor models, including B16 melanoma that was also examined in this 
thesis, that the vessel endothelium is mostly derived from the host pre-
existing vasculature. In poorly differentiated prostate carcinomas less 
than 1% of the vessels showed luminal incorporation of BMDCs, but 
these cells did not express any EC marker. Instead, the cells expressed a 
 65 
pan-leukocyte marker CD45 suggesting that despite the morphological 
similarity with the ECs, the BMDCs had retained their hematopoietic 
fate (Wickersheim et al. 2009).  
 
BMDC contribution to endothelium might be dependent on the tumor 
stage. In one study, the bone marrow contribution to tumor vascular 
endothelium was more marked in early lung carcinomas, melanomas, 
and breast adenomas, but the bone marrow-derived ECs were later 
replaced by ECs originating from the pre-existing vasculature (Nolan et 
al. 2007). This is partially in contrast to the present findings, because 
this type of time dependency was not observed in the B16 melanoma 
samples. On the other hand, Spring et al. reported that EPC homing into 
tumor vasculature would occur only during late stages of carcinogenesis 
in mouse models of pancreatic islet and liver tumors (Spring et al. 
2005). Furthermore, EPCs may also be involved in augmenting 
metastatic progression (Gao et al. 2008) not assessed in our study.  
 
BMDC structural contribution to vascular endothelium might be 
favored in certain molecular microenvironments, such as in the brain 
(Santarelli et al. 2006, Hardee, Zagzag 2012). The brain 
microenvironment might be unique as recent studies indicate that also 
tumor cells might be able to differentiate into vascular ECs in 
glioblastomas (Ricci-Vitiani et al. 2010, Soda et al. 2011). Systematic 
approaches are needed to discover the molecular determinants in those 
microenvironments that might favor differentiation of other cell types 
into ECs. One such microenvironment trigger could be the stromal 
derived factor-1, which might be an important player also in 
glioblastoma neovascularization (ZagZag et al 2006). In one study high 
numbers of BM-derived ECs were observed in a retinal injury model, 
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whereas in a B16 melanoma model with a low tumor stromal derived 
factor -1 level, BMDC-derived ECs were not detected (Madlambayan et 
al. 2009).  
 
Recent studies indicate that the existing vasculature might be quite 
heterogeneous in respect of the EC clonogenic potential and might even 
contain ECs with stem-like characteristics (Fang et al. 2012, Naito et al. 
2011, Schniedermann et al. 2010).  Therefore, one plausible explanation 
for the observed lineage shift is that in the early studies another 
circulating progenitor cell population was present in the heterogeneous 
peripheral blood extract, that was not derived from the bone marrow. 
Another possible source of error is cell fusion, which might be more 
frequent in damaging conditions, such as after irradiation, that is 
frequently employed in lineage-tracing studies (Nygren et al. 2008, 
Terada et al. 2002).  
 
2. Stromal cells and EGFR  
Stromal EGFR signaling is relatively poorly understood. In this study, 
tumor vascular NG-2-positive pericyte number and coverage decreased 
in smaller CD31+ vessels in response to the EGFR inhibitor gefitinib 
treatment. Earlier, it has been shown that the EGFR ligand heparin 
binding-EGF coordinates smooth muscle cell recruitment with Ang1 in 
vitro (Iivanainen et al. 2003). Combined inhibition of the EGFR ligand 
heparin binding-EGF together with PDGF-BB in quail embryos reduces 
pericyte recruitment, decreases basement membrane matrix deposition, 
increases vessel width, and causes vascular hemorrhages (Stratman et 
al. 2010). Anti-VEGF treatment in a mouse xenograft model of human 
lung adenocarcinoma stimulates activation of the EGFRs on the 
pericytes causing the tumors to gain resistance to anti-VEGF treatment, 
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whereas dual targeting of both EGFR and VEGFR pathways reduces the 
vascular pericyte coverage (Cascone et al. 2011). In a mouse model of 
pancreatic neuroendocrine tumorigenesis, EGFR expression was found 
both on cancer cells and the pericytes, and the EGFR inhibitor erlotinib 
decreased the coverage of NG-2 and desmin-positive pericytes on the 
endothelium, and decreased angiogenesis (Nolan-Stevaux et al. 2010). 
Taken together, these findings suggest that EGFR inhibitors might 
sometimes have useful synergistic effects with anti-angiogenic 
therapies.  
 
The numbers of perivascular BMDCs were reduced in response to 
gefitinib treatment, suggesting that the EGFR pathway might regulate 
their recruitment. One hypothesis is that the vascular pericytes 
contribute to the retention of the perivascular BMDCs in close 
proximity of the vessels and as the pericyte coverage is reduced upon 
gefitinib treatment it affects also the perivascular BMDCs counts. 
Pericytes may provide guidance for the perivascular BMDCs that crawl 
along the blood vessels during inflammatory conditions (Proebstl et al. 
2012). A second hypothesis is that this cell population comprises a 
progenitor cell population for the vascular pericytes. However, our 
preliminary analyses did not give support for the latter view 
(unpublished data). These analyses were based on the assumption that 
the vascular pericytes are located inside of the vascular basement 
membrane, whereas other perivascular cells reside outside of the 
basement membrane. However, this criterion may not be fully 
applicable to tumors, which may have several structural abnormalities 
in the vascular wall and the basement membrane (Baluk et al. 2003). In 
a mouse model of pancreatic islet tumorigenesis, it was found that a 
subset of vascular pericytes was recruited from the bone marrow as 
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PDGFR-ß+ progenitors (Song et al. 2005). Therefore, the bone marrow 
might provide progenitors for the vascular pericytes in certain tumor 
types, but this hypothesis remains to be confirmed. 
 
3. Prokineticins as potentially angiogenic proteins with a dual 
function 
In MCC, tumor cell PROK2 protein expression was associated with 
higher than median numbers of intratumoral CD8+ CTLs, and tended to 
associate with CD163+ macrophages. Tumor cell PROKR2 protein 
expression was associated with CD16+ NK cells and tended to associate 
with CD3+ T lymphocytes. Higher than median PROK2 mRNA 
expression was associated with intratumoral CD68+ and CD163+ 
macrophages. In line with these findings, several studies indicate that 
prokineticins are involved in the immune system. PROK2 expression 
has been found in the peripheral blood neutrophils, DCs, monocytes, 
and in liver resident macrophages, whereas PROK1 expression is found 
in monocytes, and in T and B cells (Dorsch et al. 2005, LeCouter et al. 
2004, Monnier et al. 2008). Of the two prokineticin receptors, PROKR1 
and PROKR2 are expressed in human CTLs and monocytes, and 
PROKR2 in human neutrophils (Zhong et al. 2009, LeCouter et al. 
2004). PROK1 and PROK2 induce a strong hematopoietic response and 
regulate monocyte chemotaxis, survival, and differentiation (LeCouter 
et al. 2004). Furthermore, human monocytes stimulated with PROK1 or 
PROK2 release proinflammatory cytokines, such as tumor necrosis 
factor-!, interleukin-1, and interleukin-12, and PROK2 induces the 
proinflammatory phenotype also in mouse macrophages (Martucci et al. 
2006). PROK2 is upregulated in several human pathological 
inflammatory conditions (Choke et al. 2009, Watson et al. 2012, 
LeCouter et al. 2004). In mouse tumors, PROK2 is expressed by tumor 
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infiltrating myeloid cells and has been found on tumor infiltrating 
neutrophils in human lung adenocarcinoma (Zhong et al. 2009, Shojaei 
et al. 2008b, Shojaei et al. 2007b).  
 
In MCC, tumor cell PROKR2 protein expression and tumor PROK2 
mRNA content correlated with the presence of MCPyV and viral T 
antigen expression in the MCC suggesting that prokineticins may 
participate in coordinating the immune response against the MCPyV. 
Patients with MCPyV –positive MCCs have better survival than those 
with MCPyV-negative cancers (Sihto et al. 2009). Accordingly, patients 
who have higher than median PROK2 mRNA content had more 
favorable survival than those with lower content.  
 
The clinical significance of the prokineticins has been studied only in 
few human tumor types with diverse results. In endometrial carcinoma, 
ovarian carcinoma, and hepatocellular carcinoma, the prokineticin 
ligands were found at low levels at the later stages of cancer, and had no 
relevance to disease outcome (Zhang et al. 2003, Ngan et al. 2006, 
Monnier et al. 2008). In prostate cancer, colorectal cancer, and thyroid 
carcinoma, prokineticins might be involved in tumor progression, as 
these tumors show elevated prokineticin expression levels as compared 
to the corresponding normal tissue (Nagano et al. 2007a, Pasquali et al. 
2011, Pasquali et al. 2006). In neuroblastoma, more PROKR1 
expression was found in advanced stages of the disease as compared to 
stage II neuroblastoma, and it was associated with metastasis (Ngan et 
al. 2007). In colorectal cancer, five-fold increase in PROK1 expression 
was found compared to normal colorectal mucosae, and PROK1 
expression was associated with metastasis and poor survival (Nagano et 
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al. 2007). This might be explained by enhanced tumor cell proliferation 
and angiogenesis upon PROK1 expression (Goi et al. 2004).  
 
Prokineticins might not be angiogenic in all tumor types, because 
neither tumor PROK1 mRNA or PROK2 mRNA content was associated 
with the density of CD31+ microvessels in MCC. However, due to the 
scarcity of the tissue material left in the serie, the microvascular density 
was analyzed only from tissue microarray samples in the present study, 
which may not be optimal for this purpose, and, therefore, the 
proangiogenic role of PROK1 and PROK2 needs further study. Yet, the 
prokineticin receptor immunostainings indicated that the MCC 
vasculature is negative for prokineticin receptors. 
 
A recent study proposed that the tumor vessel growth-promoting 
potential of the prokineticins may depend on the tumor type. In a highly 
vascularized glioblastoma xenograft, a PROK2 antagonist PKRA7 
reduced EC branching, whereas in poorly vascularized pancreatic 
cancer tissue, PKRA7 blocked myeloid cell infiltration and migration  
(Curtis et al. 2013).  In some other mouse tumor models, PROK2 
promoted vascularization via both mechanisms, and an anti-PROK2 
antibody had an additive effect to an anti-VEGF-A antibody on the 
tumor vasculature (Shojaei et al. 2007b, Shojaei et al. 2008). Therefore, 
the angiogenic signaling pathways may have the capability to regulate 
both vessel growth and host immune response. Some of these pathways 
are likely more specialized as direct stimulators of vascular cells, 
whereas other pathways are more specialized in regulating the immune 
cells. Invertebrates do not have endothelial lining in their vessels 
suggesting that in lower organisms VEGF-like proteins are mostly 
involved in the regulation of archaic immune cells (Cho et al. 2002, 
Munoz-Chapuli 2011). In higher organisms, whether these pathways 
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regulate angiogenesis, immune cell recruitment or both might depend 
on the physiological context. The blockade of one angiogenic pathway 
may reveal underlying redundancy in therapeutic settings. Therefore, 
further studies are needed to understand the roles of such redundant 
pathways in different tumor types to efficiently block tumor vascular 
growth and to enhance the host anti-tumor immune response.  
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Tumor stroma is composed of several normal cell types, such as 
BMDCs, resident immune cells, vascular cells and fibroblasts that 
modulate the tumor behavior. Recruited BMDCs may augment tumor 
blood vessel growth by providing progenitor cells for vascular 
endothelium and via paracrine secretion of pro-angiogenic growth 
factors. In this thesis, the analyses of the BMDC contribution to 
vascular endothelium with several experimental models indicated that 
the bone marrow is not a typical source of the endothelium during 
angiogenesis (I). Structural contribution of BMDCs to vascular 
endothelium may be present only in specific microenvironments that 
need further examination.  
 
Tumor microenvironment engages several angiogenic pathways that 
may augment blood vessel growth. One such pathway could be the 
EGFR pathway, that has a well-established role in the regulation of 
tumor cells, but its role in the tumor microenvironment less understood. 
The effect of the EGFR inhibitor gefitinib on tumor vascular cells and 
the BMDCs was examined in an EGFR-deficient B16 melanoma tumor 
model. Gefitinib treatment did not reduce the total microvascular 
density in the tumor, but it decreased the NG-2+ pericyte number and 
coverage of smaller CD31+ vessels (< 50 um) suggesting that the EGFR 
pathway may participate in regulating the pericyte recruitment in some 
tumors. Gefitinib treatment also reduced the amount of perivascular 
BMDCs suggesting that EGFR may be involved also in their 
recruitment or retention (II). The close perivascular position of the 
affected cells proposes that these cells might contribute to tumor 
angiogenesis via paracrine mechanisms, but this needs further analysis. 
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Prokineticins are a family of chemokine-like proteins that may have 
both immunomodulatory and angiogenic properties. PROK2 has been 
shown to mediate BMDC-dependent angiogenesis in mouse models, but 
whether this finding has any relevance in human tumors is not known. 
In MCC, tumor PROK1 or PROK2 mRNA content did not correlate 
with tumor microvascular density proposing that prokineticins are not 
involved in tumor angiogenesis in all tumor types. Instead, high tumor 
PROK2 mRNA content was associated with presence of MCPyV DNA 
and viral large T-antigen expression in MCC. Furthermore, MCCs with 
a high PROK2 mRNA content had higher numbers of tumor infiltrating 
CD68+ and CD163+ macrophages and more favorable survival than 
MCCs with a low PROK2 content. The presence of PROK1 mRNA in 
the tumor was associated with MCPyV -negative MCCs and tended to 
associate with poor survival (III). Taken together, the prokineticins may 
be involved in mediating the immune response in MCC, but their role in 
tumor angiogenesis in MCC requires further evaluation.   
 +
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